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 Craniosynostosis is a disorder characterized by the premature fusing of cranial sutures in 
an infant. Premature closure of these sutures can lead to detrimental consequences on the 
development of a child. The two broad categories of craniosynostosis are classified as syndromic 
and nonsyndromic. Nonsyndromic craniosynostosis involves only the fusion of one or more 
sutures, whereas syndromic craniosynostosis involves other abnormalities throughout the body 
of the affected individual. Two of the families analyzed in this study were of the syndromic 
nature, and known FGFR mutations were discovered. However, phenotypical features 
documented in association with these mutations differed from our individuals. Two families 
affected with nonsyndromic sagittal synostosis were also analyzed. Within one of these families, 
three candidate mutations were identified as possible disease causing mutations. These mutations 
were found in the genes ITGAV, SLC30A9, and BAMBI. Here we analyze the function of these 
proteins and determine the significance of the role they may play in nonsyndromic 
craniosynostosis.  
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Chapter 1: Introduction 
The human brain is by far one of the most complex and intricate organs to develop during 
embryogenesis. Without the sophisticated neural networks of the brain, the cells of the body have 
no control center. Anything preventing or hindering the development of the brain can have 
detrimental effects on the developing fetus, and can often lead to fatality. Craniosynostosis is one 
of the many disorders that affect the development of the brain by preventing proper growth.  
Craniosynostosis is defined as “a birth defect that causes one or more of the sutures on an 
infant’s skull to close earlier than usual.” (Kinsman et al. 2011). Premature closing of these 
sutures can lead to abnormal development caused by the inability of the bones to move and 
expand in accordance with the growth of the brain.  
Cranial Bone Development 
Human skull bones begin to develop during 23-26 days of gestation. Formation of the 
cranial bones occurs via intramembranous ossification, a process that lacks the cartilage 
intermediate that is found within most of the bones of the body (Beederman, et al. 2014). 
Intramembranous ossification is defined as “the direct conversion of mesenchymal tissue into 
bone” (Gilbert, et al. 2000). During intramembranous ossification in the skull, neural crest-
derived mesenchymal cells proliferate and condense. Some of these cells become capillaries, 
while others differentiate into osteoblasts and begin to secrete a collagen-proteoglycan matrix. 
This matrix has the ability to bind calcium salts, allowing the calcification process to proceed. 
Bone morphogenetic proteins (BMP) from the head epidermis are thought to influence the 
conversion of the mesenchymal cells into osteocytes (Gilbert, et al. 2000). These mesenchymal 
cells are located between the dermal mesenchyme and the meninges of the brain. Areas that will 
eventually form the skull sutures remain undifferentiated (Beederman, et al. 2014).  
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One transcription factor that is crucial to the development of bones throughout the body 
is runt-related transcription factor 2 (RUNX2, aka CBFA1). RUNX2 is a BMP activated 
transcription factor that regulates the transformation of mesenchymal cells into osteoblasts. 
Confirmation of this role was obtained via a RUNX2 homozygous knockout study in mice 
(Gilbert, et al. 2000). Prior to determination of RUNX2’s function, Komori et al. (1997) and Otto 
et al. (1997) showed that homozygous deletion of the RUNX2 gene caused fatality immediately 
after birth. Mice with this mutation had only cartilaginous skeletal models, thus exhibiting a 
complete lack of bone through elimination of both endochondral and intramembranous 
ossification. Heterozygous knockouts of RUNX2 showed a complete lack of skull suture fusion, 
as well as stunted growth and clavicle absence, a phenotype similar to cleidocranial dysplasia 
(CCD). This study led to the determination that CCD in humans is caused by heterozygosity of 
the RUNX2 gene (Mundulos, et al. 1997). 
Skulls are comprised of two frontal bones, two parietal bones, two temporal bones, one 
sphenoid bone, and one occipital bone (Figure 1). Sutures are classified as the fibrous areas 
where two bones come into contact with one another. Fontanelles are the specific location where 
multiple sutures come into contact with each other and there is often a lack of bone in this area, 
thus creating a “soft spot”. There are two fontanelles in the newborn skull, the anterior fontanelle 
and the posterior fontanelle (Figure 1) (Beederman, et al. 2014) 
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Figure 1. Anatomical drawings of a newborn skull from a lateral and vertex view. Taken and 
edited from http://www.nlmnih.gov/medlineplus/ency/imagepages/1127.htm 
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Cranial Sutures 
A newborn skull contains five main sutures: metopic, lambdoid, coronal, sagittal, and 
squamous, as shown in Figures 1 and 2 (Carlo et al. 2011). The sagittal suture lies most 
superiorly on the newborn skull and is located between the two parietal bones. Two of the 
sutures are split into right and left sides, the coronal and lambdoid sutures. The coronal sutures 
are located between the two frontal and parietal bones, and the lambdoid sutures are between the 
supraoccipital and parietal bones. In the same line as the sagittal suture lies the metopic suture, 
located between the two frontal bones. Most posteriorly on the skull is the squamosal suture, 
located between the temporal, parietal, and sphenoid bones (Beederman, et al. 2014). 
 
Figure 2. Three-dimensional computed tomography reconstructions of a 4-week-old patient with 
normal suture development (A–C). Anterior (A), vertex (B), and lateral (C) views. (A–C) 
Typical skull contour with patent sutures. AF, anterior fontanelle; M, metopic suture; S, sagittal 
suture; Cor., coronal suture; Sq., squamosal suture; L, lambdoid suture. Taken from Beederman, 
et al. 2014. 
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Sutures form in an interdigitated pattern caused by the expression of several classes of 
molecules. Using a mouse model, several osteoblastic proteins were localized at the osteogenic 
fronts and within the sutural mesenchyme of the calvarial bones (frontal, parietal, and 
interparietal). RUNX2, BMP (both described above), and bone sialoprotein (BSP) are three of 
the proteins expressed at the osteogenic fronts of the cranial bones. BSP is an extracellular 
matrix protein produced by osteoblasts and is thought to play a role in the process of bone 
mineralization. As development progresses, expression of both BSP and RUNX2 becomes more 
restricted to areas of high osteogenic activity, or sutural bone ends, as development progresses. 
Two transcription factors thought to regulate osteogenic lineage crucial to the 
development of the skull are msh homeobox 2 (MSX2) and twist family bHLH transcription 
factor 1 (TWIST1). These two have been found to be extensively expressed in the cranial 
mesenchyme. Similar to BSP and RUNX2, as development progresses, TWIST1 and MSX2 
expression become restricted to mid-sutural mesenchyme between the osteogenic fronts. As 
mesenchymal cells differentiate into mature osteoblasts, their gene expression profile changes 
from TWIST1 and MSX2 to FGFR2c and MSX2. All transcripts of the fibroblast growth factor 
receptor (FGFR) genes FGFR1, FGFR2, and FGFR3, with the exception of the FGFR1b and 
FGFR3b isoforms, are localized within the sutural mesenchyme. FGFRs are a family of receptor 
tyrosine kinases that bind fibroblast growth factors (FGF). Most notably, FGFR2c transcripts 
have been detected with high intensity in the sutural osteogenic fronts of the developing skull 
(Rice, et al. 2003).  
In Rice et al. (2003) upstream mediators and downstream targets of BMPs and FGFs 
were evaluated through a study involving beads coated with different FGF or BMP proteins. 
Results showed that FGF4 upregulated expression of MSX1, BMP2 upregulated MSX2, and 
6 
 
BMP4 was found to upregulate both MSX1 and MSX2.  FGF2 was shown to induce TWIST1 
mRNA. FGF4 beads were placed on the osteogenic fronts caused accelerated sutural closure, 
similar to craniosynostosis phenotypes. These studies gave an indication of the signaling 
networks involved in suture biology. 
At approximately 18 months of age, the metopic suture begins to fuse, making it the first 
suture to fuse in a typical infant (Morriss-Kay, et al. 2005). The last suture to fuse is the sagittal 
suture, a process that generally does not take place until approximately 25 years of age 
(Beederman, et al. 2014). 
The patency of the sutures corresponds to the growth of the brain throughout the 
development of a child. The brain experiences a rapid growth through the first few years of the 
child’s life, reaching approximately 70% of its final weight by 2 years of age (Huelke, et al. 
1998). The brain then begins to plateau and does not reach its estimated adult size until around 
early adolescence (Derderian, et al. 2012). Thus, it is crucial for the sutures to remain patent to 
avoid increased intracranial pressure within the skull. Increased intracranial pressure can damage 
the brain or spinal cord by pressing on certain areas of the brain and restricting blood flow, 
causing a lack of oxygen to that area. This can lead to detrimental consequences on the 
development of the child. Some of these consequences include developmental delay, 
hydrocephalus, visual abnormalities, airway impairment, and orthodontic defects (Anantheswar, 
et al. 2009). 
Syndromic Craniosynostosis  
 There are two broad categories of craniosynostosis: syndromic and nonsyndromic. The 
overall prevalence of craniosynostosis is approximately 1 in 2500 births (Johnson, et al. 2011). 
Syndromic craniosynostosis accounts for approximately 25% of all cases and can result from 
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over 180 monogenic syndromes, such as Crouzon, Apert, Pfeiffer, and Muenke syndrome 
(Greenwood, et al. 2014). What sets these disorders apart from nonsyndromic craniosynostosis is 
that the premature fusing of the skull bones occurs with other features such as exophthalmos, 
midface hypoplasia, uncharacteristic facies, and limb abnormalities (Derderian, et al. 2012). 
Ethnic prevalence within syndromic craniosynostosis patients varies depending on which 
syndrome the individual has.  
Nonsyndromic Craniosynostosis  
Nonsyndromic craniosynostosis (NSC), which is the focus of this study, occurs when the 
affected individual shows no other clinical features aside from the skull anomalies. No clear 
association has been discovered between ethnicity and NSC. Single suture forms represent a 
majority of the nonsyndromic cases and are classified according to which suture is fused at the 
birth of the child (Lattanzi, et al. 2012). Complex suture synostosis, found in approximately 5-
15% of nonsyndromic cases, occurs when multiple sutures are fused (Morriss-Kay, et al. 2005). 
Complex synostosis phenotypes depend upon which sutures are fused. The phenotype is often a 
combination of the clinical features of those categories (Greenwood, et al. 2014). 
Sagittal synostosis, or scaphocephaly, is the most common type of nonsyndromic 
craniosynostosis, with a percentage of roughly 45-50% of nonsyndromic cases. Scaphocephaly 
occurs in approximately 1 in 5,000 births (Greenwood, et al. 2014). This type arises in a male to 
female ratio of 2.5:1. Sagittal suture fusion results in a long and narrow skull, leading to the 
name “scapho” meaning boat in Greek. (Figure 3a) 
The second most common type is coronal synostosis, or anterior plagiocephaly. Coronal 
synostosis can either be unicoronal or bicoronal, affecting one or both sides of the coronal suture. 
It is more common for coronal synostosis to be seen in the unicoronal presentation. This makes 
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up approximately 25-30% of NSC cases and shows female prevalence with a 1:2.3 male to 
female ratio (Lattanzi, et al. 2012). Anterior plagiocephaly is clinically characterized by 
flattening of the forehead on the affected side, often leading to an elevated eye socket or deviated 
nose (Garza, et al. 2012). (Figure 3b) 
Metopic craniosynostosis is the premature fusion of the metopic suture and accounts for 
approximately 14% of NSC cases.  This category has a male to female ratio of 3.3:1 
(Greenwood, et al. 2014). Metopic synostosis is also known as trigonocephaly due to the 
triangular shape of the forehead with bifrontal and bitemporal narrowing, as well as parietal and 
occipital prominence (Garza, et al. 2012). (Figure 3c) 
Lambdoid synostosis, the least common, is found in only 3% of NSC cases (Lattanzi, et 
al. 2012). Also called posterior plagiocephaly, lambdoid synostosis presents with an occipital 
dysmorphism involving a mastoid bulge and a thick ridge along the affected side of the lambdoid 
suture  (Garza, et al. 2012). This phonotypical presentation is similar to the coronal synostosis, 
but on the posterior aspect of the child’s head. (Figure 3d) 
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Figure 3. (A) Sagittal craniosynostosis from a vertex and lateral view. (B) Right coronal 
synostosis from an anterior and vertex view. (C) Metopic craniosynostosis from an anterior and 
vertex view. (D) Left lambdoid craniosynostosis from an anterior and posterior view. Taken 
from Ciurea, et al and Pincus, et al.  
 
 
A 
B 
C 
D 
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Treatment Options 
 Due to the lack of knowledge surrounding the causes of nonsyndromic craniosynostosis, 
prevention is not yet a possibility. The only treatment option available at this time is surgical 
intervention. Surgery to separate fused sutures must be performed when the affected child is still 
within his or her first year of life. The primary goals of surgical intervention are to relieve 
pressure on the brain and separate the sutures in order to allow the child’s head to grow, as it 
should during normal development (Kinsman et al. 2011). Craniofacial surgery is a combination 
of neurosurgery, plastic surgery, occuloplastics, ENT, and neck specialties. (Anantheswar, et al. 
2009) Proper timing of surgery is vital to the survival of the infant. The common philosophy is to 
perform surgery as soon as the child is able to withstand the stress (Garza, et al. 2012). 
 Complications involved in an open surgical repair include bleeding, infection, 
cerebrospinal fluid leak, failure of re-ossification, contour irregularity, meningitis, stroke, and 
even death. Previous research has shown that patients who underwent surgery prior to 6 months 
of age had a less successful outcome and often needed a second operation. Thus, the general 
consensus among surgeons is to perform surgery between 6 and 12 months of age. Current 
research is focusing on understanding the genetic basis of craniosynostosis in order to provide 
opportunities for earlier and more specific interventions, as well as targeted gene therapy for the 
prevention of premature suture fusion (Garza, et al. 2012). 
Genetics of Syndromic Craniosynostosis  
FGFR Genes 
Although a clear genetic background for all types of nonsyndromic craniosynostosis has 
not been determined yet, several genes have been identified for syndromic craniosynostosis. A 
group of genes, the FGFRs, are known to cause a craniosynostosis phenotype. FGFRs, as 
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described above, bind FGFs, a family of at least 22 signaling molecules that play a regulatory 
role during embryonic development (Hughes, et al. 1997). FGF signaling is crucial to 
endochondral and intramembranous ossification (Lattanzi, et al. 2012). There are four members 
of the FGFR family, labeled FGFR1, FGFR2, FGFR3, and FGFR4. The binding of FGFRs to 
their ligand is promiscuous, meaning any receptor can bind any one of the signaling molecules. 
Each FGFR has a cytoplasmic tyrosine kinase domain, a transmembrane domain, and an 
extracellular domain consisting of three immunoglobulin (Ig)-like domains. Ligands bind 
between the second and third Ig-like domains, allowing the receptors to dimerize and an 
intracellular signaling cascade to proceed (Robin, et al. 1998). 
Despite widespread tissue localization, mutations in the FGFR family primarily lead to a 
variety of bone abnormalities during development. As shown in Figure 4, several 
craniosynostosis phenotypes have been associated with three of the FGFR genes. FGFR 
mutations have also been identified for multiple other disorders such as achondroplasia, 
hypochondroplasia, Antley-Bixler syndrome, and Saethre-Chotzen. There are craniosynostosis 
syndromes with identified FGFR mutations, as shown in Table 1. Of the eight FGFR related 
craniosynostosis syndromes, six can be diagnosed by characteristic facial features, hand and foot 
abnormalities, and skull shape. These six are Pfeiffer syndrome, Apert syndrome, Crouzon 
syndrome, Beare-Stevenson syndrome, Jackson-Weiss syndrome, and Crouzon with acanthosis 
nigricans (AN). The other two, Muenke syndrome and FGFR2-related isolated coronal 
synostosis, require molecular genetic testing. Muenke syndrome may have uni- or bicoronal 
synostosis or megalocephaly without craniosynostosis, thus requiring an FGFR3 P250R mutation 
for diagnosis. This same mutation has been associated with nonsyndromic coronal 
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craniosynostosis. FGFR2-related isolated coronal synostosis is characterized by uni- or bicoronal 
craniosynostosis only (Robin, et al. 1998). 
The most characterized FGFR1 mutation that has been shown to cause syndromic 
craniosynostosis is the Pfeiffer syndrome P252R missense mutation. As for FGFR3, the only 
craniosynostosis mutation identified is the A391E mutation causing Crouzon syndrome. 
However, individuals with only Crouzon syndrome are unlikely to have a mutation in FGFR3 
(Robin, et al. 1998). All other FGFR3 mutations identified cause varying types of skeletal 
dysplasia. Currently, no mutations in FGFR4 have been identified to cause craniofacial 
disorders.  
Multiple mutations in the FGFR2 gene have been identified in several different 
syndromic craniosynostosis disorders. Apert syndrome is caused by both the S252W and P243R 
mutations. Mutations within the third immunoglobulin domain have been shown to cause 
Crouzon, Pfeiffer, and Jackson-Weiss syndrome, as noted in Figure 4. Different mutations at the 
same residue (W290G, W290R, W290H, W290C) result in either Pfeiffer syndrome or Crouzon, 
suggesting the role of epigenetics factors, modifier genes, or control sequences (Robin, et al. 
1998).  
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Table 1. FGFR Related Craniosynostosi Disorders 
 Craniofacial Extremities Intellect Skin Other 
Crouzon 
syndrome 
Coronal synostosis 
Proptosis 
External strabismus 
Mandibular 
prognathism 
Normal Normal Normal Hydrocephalus 
Tonsillar herniation 
Sacrococcygeal tail 
Crouzon 
syndrome with 
AN 
Coronal synostosis 
Proptosis 
External strabismus 
Mandibular 
prognathism 
Normal Normal Acanthosis 
nigricans 
None 
Apert syndrome Turribrachycephaly 
Midface hypoplasia 
Syndactyly 
Rhizomelic 
shortening 
Elbow ankyloses 
Intellectual 
disability 
Normal Fused cervical 
vertebrae 
Cardiac defects 
Gastrointestinal 
defects 
Ovarian 
dysgerminoma 
Pfeiffer Type 1 Midface hypoplasia Broad and medially 
deviated thumbs and 
great toes 
Bradydactyly 
Normal Normal Hearing loss 
Hydrocephalus  
Pfeiffer Type 2 Cloverleaf skull 
Extreme proptosis 
Broad and medially 
deviated thumbs and 
great toes 
Ankyloses of 
elbows and knees 
Bradydactyly  
Intellectual 
disability 
Normal Choanalstenosis 
Laryngotracheal 
abnormalities 
Hydrocephalus 
Seizures 
Sacrococcygeal 
eversion 
Cleft palate  
Pfeiffer Type 3 Turribrachycephaly 
Extreme proptosis 
Broad and medially 
deviated thumbs and 
great toes 
Ankyloses of 
elbows and knees 
Bradydactyly 
Intellectual 
disability 
Normal Choanalstenosis 
Laryngotracheal 
abnormalities 
Hydrocephalus 
Seizures 
 
Muenke 
syndrome 
Variable 
Uni or bilateral 
coronal  
Midface hypoplasia 
Megalocephaly 
Ocular hypertension 
Variable  
Carpal-tarsal fusion 
Brachydactyly 
Carpal bone 
malsegregation 
Coned epiphyses 
Normal to 
mild 
intellectual 
disability 
Normal Bilateral, symmetrical 
low to mid frequency 
hearing loss 
Osteochondroma 
Jackson-Weiss Mandibular 
prognathism 
Broad and medially 
deviated great toes 
Short first 
metatarsal 
Calcaneocuboid 
fusion 
Abnormal tarsals 
Normal Normal None 
Beare-Stevenson Moderate to severe 
midface hypoplasia 
Abnormal ears 
Natal teeth 
Furrowed palms and 
soles 
Intellectual 
disability  
Widespread cutis 
gyrate 
Acanthosis 
nigricans 
Prominent 
umbilical stump 
Bifid scrotum 
Prominent labial 
raphe/rugated labia 
majora 
Pyloric stenosis 
Anterior anus 
FGFR2-related 
isolated coronal 
synostosis  
Unilateral coronal 
synostosis 
Normal Normal Normal Normal  
 
14 
 
Figure 4. Pathogenic missense mutations within FGFR1, 2, and 3. Mutations whose mechanisms 
of action have been elucidated are in red letters and underlined. Taken from 
http://www.med.nyu.edu/mohammadi/LabPage/fgfr_mut.html  
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TWIST1 
 TWIST1 mutations have been found to cause Saethre-Chotzen syndrome, an autosomal 
dominantly inherited disorder involving a coronal synostosis phenotype, ptosis, widely spaced 
eyes, and minor abnormalities of the hands and feet (Robin, et al. 1998). This protein functions 
within the cell nucleus as a transcription factor and contains two nuclear localization signal 
sequences. Mutations within this gene cause the protein to either translocate to the nucleus by 
itself or inhibit its ability to enter the nucleus at all. TWIST1 received its name due to a complete 
eversion of the head seen in homozygous mutations of Drosophila (Lattanzi, et al. 2012). Due to 
the prevalence of FGFR2 and FGFR3 mutations seen within individuals with Saethre-Chotzen 
syndrome, it is speculated that TWIST1 is required for FGF signaling. Previous studies have 
shown that as TWIST1 levels decrease, FGFR distribution is altered, causing a reason to believe 
they are located within the same pathway (Rice, et al. 2003). TWIST1 is also thought to perform 
a regulatory role for BMP, and TGF-β signaling (Qin, et al. 2012). Mutations have been found in 
unaffected parents, showing a high variability of expression and reduced penetrance of TWIST1 
mutations (Lattanzi, et al. 2012). 
MSX2 
 The first mutation identified for a craniosynostosis phenotype was a heterozygous MSX2 
missense mutation. MSX2 encodes a homeobox-containing transcription factor and a missense 
mutation P148H acts to stabilize DNA binding (Neilson, et al. 1995). This mutation was 
originally identified in a large three generation family containing 13 affected individuals. These 
individuals had a rare syndrome, later named Boston-type craniosynostosis for the location of the 
originally described family. Boston-type craniosynostosis is a highly penetrant autosomal 
dominant disorder that presents with forehead retrusion, frontal bossing, turribrachycephaly, and 
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the Kleeblattschaedel deforming (trilobular, or cloverleav) skull anomaly. None of the 
individuals in the family had any hand or foot abnormalities. It has not been documented which 
sutures were fused within each individual, but severity increased with each generation (O’Niell, 
et al. 2013).  
Genetics of Nonsyndromic Craniosynostosis  
Genetics of Nonsyndromic Craniosynostosis  
FGFR – Coronal Synostosis  
As stated previously, FGFR3 P250R mutations have been associated with isolated 
coronal synostosis, as well as Muenke syndrome. In one study, 4 out of 37 individuals with 
isolated coronal synostosis were found to have an FGFR3 P250R mutation. Although it is rare to 
see a familial trend with isolated synostosis, 3 out of these 4 individuals had a father with the 
same change, leading to the possibility of reduced penetrance of this mutation (Gripp, et al. 
1998). Another study found an FGFR3 P250R mutation in 29 out of 76 individuals with isolated 
coronal synostosis (Thomas, et al. 2005). FGFR2-related isolated coronal synostosis has also 
been shown to link FGFR2 mutations to a specific NSC presentation. 
FREM1 – Metopic Synostosis  
 One gene known to be associated with nonsyndromic metopic craniosynostosis is  
FREM1. FREM1 encodes an extracellular matrix protein that plays a role in epidermal 
differentiation, craniofacial development, and renal development. FREM1 stands for FRAS1 
(Fraser syndrome 1 homolog) related extracellular matrix 1. FRAS1 encodes a protein that 
functions to regulate epidermal-basement membrane adhesion and organogenesis during 
development (Pavlakis, et al. 2011). One study of 109 patients with metopic craniosynostosis 
identified 5 de novo CNVs and 3 missense mutations in the FREM1 coding region (Vissers, et al. 
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2011). Further analysis of FREM1 in mouse models showed localization of the protein around 
the posterior frontal suture, the equivalent to the metopic suture. This finding was further 
confirmed by premature fusion of this suture in two different mouse lines carrying distinct 
FREM1 loss-of-function mutations. It is speculated that FREM1 can also bind FGFs via 
chondroitin sulfate proteoglycan repeats of the NG2 proteoglycan in the FREM1 protein 
(Vissers, et al. 2011). 
Zebrafish as a Model Organism 
 One model organism that has been used for craniosynostosis studies is the zebrafish 
(Danio rerio), a small freshwater cyprinid fish. The zebrafish is a powerful model organism 
often used to study vertebrate embryogenesis, morphogenesis, and gene function (Quarto, et al. 
2005). In contrast to mouse embryos, zebrafish develop ex utero, or outside the mother’s body, 
allowing for visual analysis of early developmental processes. In addition to the external 
development, the craniofacial elements lie below a thin layer of tissue, allowing them to be 
easily observed in both fixed and live animals.  Zebrafish also have short generation times and 
high fecundity, allowing for rapid genetic analysis (Dooley, et al. 2000). Moreover, a high 
degree of genetic and developmental conservation exists between zebrafish and humans (Grova, 
et al. 2012).  
Zebrafish skulls have frontal, parietal, and occipital cranial bone elements with associated 
sutures, similar to those found in mammals (Figure 5). Also similar to mammalian development, 
the skull bones form via intramembranous ossification where the frontal bones are neural crest 
derived and the parietal bones are mesoderm derived. Interfrontal, sagittal, coronal, and 
lambdoid sutures are all found in the zebrafish skull in an arrangement similar to vertebrate 
organisms. In contrast to humans, the most anterior portion of the zebrafish skull remains patent 
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(Grova, et al. 2012). Osteogenesis is first detected around 27 days post fertilization (dpf), 
beginning at the frontal bone, and is completed by day 51. However, pre-patterning of the cranial 
sutures in the mesenchyme can be seen at 21 dpf, as shown in Figure 6. In zebrafish, cranial 
suture patterning is an active autonomous process, independent of osteogenesis, although, the 
cranial sutures can easily be detected prior to onset of osteogenesis (Quarto, et al. 2005). 
 What is known about craniosynostosis studies in zebrafish involves the study of a 
heterozygous mutation of cytochrome P450, family 26, subfamily B, polypeptide 1 (CYP26B1), 
an enzyme responsible for retinoic acid degradation. Retinoic acid has been well documented to 
have teratogenic effects in the limb and craniofacial skeleton. This study showed that zebrafish 
with this mutation developed coronal synostosis. Retinoic acid functions as a morphogen, 
establishing concentration gradients over all developmental fields in the developing embryo. A 
predicted model for retinoic acid function is that high levels promote osteoblast to osteocyte 
transitioning to produce terminally differentiated osteoclasts. Without the negative regulation of 
CYP26B1, accelerated maturation of the osteoblast cells to osteoclast cells could cause 
mineralization of the structure, causing craniosynostosis when it occurs in the skull bones (Laue, 
et al. 2011). 
The zebrafish is an organism that will provide an opportunity to gain more insight into 
the molecular mechanisms governing skull development and cranial suture patterning.  
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Figure 5. Morphology of zebrafish skull vault. Skulls were dissected from larvae, juvenile and 
adult zebrafish and analyzed under a stereomicroscope. Note the cranial sutures (arrows) and the 
frontal bone (F), parietal bone (P), and supraoccipital bone (SOC) of the skull vault. Taken from 
Quarto, et al. 2005.  
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Figure 6. Calvarial bone osteogenesis. Larvae and juvenile zebrafish were fixed in 4% 
paraformaldehyde and stained with Alizarin Red to detect bony tissue. Note the presence of 
ossification (arrow) starting from the most anterior part of the skull (frontal bone) in 27-dpf 
specimens. At 51 dpf, complete bone maturation of the skull vault is observed. Taken from 
Quarto, et al. 2005. 
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Whole Exome Sequencing  
 Whole exome sequencing (WES) is a next-generation sequencing technique that has the 
potential to uncover the causes of a large number of rare, mostly monogenic disorders, as well as 
predisposing variants in common diseases and cancers. Human exomes constitute approximately 
1.5% of the genome, but contain approximately 85% of disease causing mutations in monogenic 
disorders. Compared to whole genome sequencing (WGS), the cost is much lower, leading to a 
practical application in clinical genetic diagnostics (Rabbani, et al 2014). However, WES is 
primarily focused on the coding regions and splice-site variants in annotated genes, which 
creates the possibility for a missed mutation in a region of noncoding RNA, epigenetic 
regulation, control sequences, intronic regions, mitrochondrial DNA, or uniparental disomy.  
 Ethical concerns over WES include how much information the patient should be given 
regarding the results. For example, how many relatives of the patient should be informed? Or if a 
mutation identified could lead to increased susceptibility for a late-onset disease, should they be 
informed? As WES becomes cheaper and more clinically available, insurance companies could 
take advantage of the information, leading to higher premiums for patients who have the 
potential to develop a certain disease later in life (Rabbani, et al. 2014).  
 Although there are ethical and legal concerns over WES, the ability to identify a majority 
of disease causing mutations is a significant advancement in the medical world and provides the 
possibility of personalized medicine in the coming years.   
Aims 
 The goal of this study is to provide insight into possible causes of craniosynostosis 
through the evaluation and analysis of several affected individuals and their families. After 
analysis of each individual’s genome, several candidate genes will be located and investigated to 
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determine the likelihood of their involvement in skull and suture development. Final steps will 
involve model organism testing to determine whether mutation of each candidate gene causes a 
phenotype similar to that of craniosynostosis in humans.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
Chapter 2: Materials and Methods 
Patients 
 Patients affected with craniosynostosis were ascertained from the Virginia 
Commonwealth University Center for Craniofacial Care under the direction of Dr. Jennifer 
Rhodes. Blood samples were obtained from each patient, as well as available family members. 
Of the 100 samples that have been collected, 18 were used for this study. Patient samples were 
labeled with CS and a number correlating to the order in which they joined the study.  
This study analyzed a three-generation family that included an affected son (CS-58), 
affected mother (CS-59), unaffected father (CS-60), and affected maternal grandmother (CS-61) 
(Figure 7a). CS-58 presented with left coronal, left lambdoid, and squamous synostosis. He also 
had scalloping of the occipital bone and an unusually large anterior fontanelle. This patient had 
normal hearing, but low set ears. He showed no evidence of midface hypoplasia, but his palate 
was slightly arched and his left eye displayed ptosis with mild proptosis. This patient was 
diagnosed clinically as having atypical Crouzon based upon these findings and the absence of 
limb abnormalities. The affected sutures of the mother and maternal grandmother are unable to 
be ascertained for our study due to the natural fusion of the skull bones over time, obscuring the 
premature fusion of specific sutures. Genetic testing of CS-58 screened for FGFR3 mutations, 
with no mutations found.   
Two trios were also involved in this study. The first trio included a set of unaffected 
parents (CS-54 and CS-55) with their affected daughter (CS-39) (Figure 7b). CS-39 was born 
with complex synostosis involving the metopic, bicoronal, and lambdoid sutures. She also 
presented with proptosis, a tense and bulging fontanelle, midface hypoplasia, subsquamosal 
bulging, noisy breathing with gurgling, Chiari malformation, and turricephaly with a coned 
superior occiput and flattened lower occiput. In addition to her craniofacial abnormalities, she 
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struggled with delayed gastric emptying, seizures, and kyphosis of her lower thoracic/upper 
lumbar spine. She was diagnosed as having Pfeiffer Type 3. Genetic screening was performed on 
CS-39 in order to test for TWIST1 mutations, FGFR1 P252R mutation, FGFR3 P250R mutation, 
and sequencing of FGFR2 exons 3a, 3c, 8, and 10. All results revealed no mutations. The second 
trio family included an affected father (CS-65), unaffected mother (CS-66), and affected 
daughter (CS-64) (Figure 7c). CS-64 was born with sagittal synostosis, and it is believed that 
CS-65 was also affected with sagittal synostosis based upon his clinical appearance. No genetic 
screening of CS-64 or CS-65 was performed.  
We also included CS-14 and CS-15, a pair of monozygotic twins discordant for 
craniosynostosis (Figure 7d). CS-14 was born affected with nonsyndromic sagittal synostosis. 
No genetic screening had been performed on the twins.  
 Also included in our study was a family of six individuals, including an unaffected 
mother (CS-7), unaffected father (CS-2), and four of their children (CS-3, CS-4, CS-5, CS-6) 
(Figure 7e). CS-3 and CS-4 were born affected with sagittal synostosis. CS-5 was born with 
midline cutaneous meningioma, but did not present with a craniosynostosis phenotype. CS-6 is 
unaffected. No genetic screening of this family was performed.  
 
 
 
 
 
 
 
25 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 7. Pedigrees for (A) three generation family CS-58, CS-59, CS-60, and CS-61 segregating 
craniosynostosis in an autosomal dominant pattern; (B) trio family CS-39, CS-54, and CS-55; 
(C) trio family CS-64, CS-65, and CS-66 with autosomal dominant segregation; (D) 
monozygotic twins CS-14 and CS-15; (E) family of six with CS-2, CS-3, CS-4, CS-5, CS-6, and 
CS-Filled in circles are affected individuals. The hatch marked square is the individual with 
cutaneous midline meningioma. Arrows indicate the proband of each family 
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Whole Exome Sequencing  
Whole exome sequencing for all individuals, excluding the six-member family, was 
performed by Beckman Coulter Genomics, Inc. A hard drive was provided including the variant 
call format (vcf) files, Standard Alignment and Mapping format (SAM file), and Binary 
Alignment and Mapping format (BAM file). The BAM file is a compressed version of the SAM 
file and both contain aligned and non-aligned reads. Beckman Coulter Genomics, Inc uses 
Agilent SureSelect V5 target capture covering approximately 50Mb.  
Sequence mapping was performed on a genome reference sequence using the Burrows-
Wheeler Alignment tool (BWA) version 0.6.1-r104 with default parameters. Library fragment 
sizes from the BWA mapping were estimated with Dindel version 1.01 using default parameters. 
Read map proportions are estimated using samtools version 1.18 “view” command with a BED 
file reflecting the extent of the baits present in the target enrichment kit used, the hsV5 kit. Table 
3 statistics are obtained using bamtools version 2.2.3 “stats” command. Table 4 duplicate read 
pairs are estimated by PICARD version 1.86 “MarkDuplicates”, samtools “Rmdup”, and 
FastQC. “Pairs needed” is obtained by extrapolating the average coverage with duplicates 
resulting from the sequence pairs generated, for libraries not reaching the quoted coverage. 
Whole exome sequencing for the six member family was performed by the Nucleic Acid 
Core. Dr. Todd Web performed the quality control and mapping, and Dr. Tim Bigdeli did the 
filtering. Filtering was performed to include recessive and spontaneously inherited alleles. 
Quality control filters were similar to the ones described for all other families. 
Mendelian Error Analysis 
 Analysis to determine relationships between family members Mendelian errors was 
performed using the “plink” program. This program outputs several files detailing the nature of 
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any Mendelian error found within each family. In order to determine if the number of errors 
within a family significantly differed from the number of errors in an unrelated family, three 
simulations were run. Each simulation used a fake pedigree file using the proband of each family 
(CS-39, CS-58, or CS-64) with unrelated parents. An example of a fake pedigree file is shown in 
Table 2a and compared to the real pedigree shown in Table 2b, where a 0 indicates a missing 
value. The mean of the three trials was calculated and used to run a one tailed t-test against the 
number of real Mendelian errors found. Mendelian errors were performed with the raw data prior 
to any filtering.  
 For the CS-14 monozygotic twin pair, past twin studies were used to compare the amount 
of errors found after quality control filtering. Plink Mendelian error analysis was unable to be 
performed on this family because parental data is required and not available   
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Table 2a 
 
Individual Family Father Mother 
CS-39 1 CS-65 CS-61 
CS-65 1 0 0 
CS-61 1 0 0 
CS-64 2 CS-15 CS-54 
CS-15 2 0 0 
CS-54 2 0 0 
CS-58 3 CS-55 CS-66 
CS-55 3 0 0 
CS-66 3 0 0 
 
 
 
Table 2b 
 
Individual Family Father Mother 
CS-39 1 CS-55 CS-54 
CS-54 1 0 0 
CS-55 1 0 0 
CS-64 2 CS-65 CS-66 
CS-65 2 0 0 
CS-66 2 0 0 
CS-58 3 CS-59 CS-60 
CS-59 3 0 0 
CS-60 3 0 0 
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Filtering of Variants  
KGGseq was used for prioritization of causal variants within each individual’s exomes. 
KGGseq uses a three-level filtration framework to organize the variants. The first level of 
filtration is at the genetic level. This level excludes variants outside of identity by descent (IBD) 
regions and variants conflicting with disease inheritance patterns. The CS-14 twin pair was 
filtered to search for any variants that differed between the twins using the de novo filter. The 
CS-39 trio was filtered to include only recessively inherited homozygous alternate alleles and de 
novo mutations. Both the CS-64 and the CS-58 families were filtered to include dominantly 
inherited heterozygous alleles. Also within this filtration level are quality control boundaries in 
order to ensure each variant that is kept adheres to the quality standard set by the user.  
The second level of filtration is the variant-gene level, which further analyzes each 
variant kept from the genetic level. The primary purpose of this level is to filter out mutations 
that are unlikely to cause diseases. This involves the comparison of the variants with information 
pulled from the 1000 Genomes project, dbSNP database, and/or NHLBI GO Exome Sequencing 
Project. Genome builds available for comparison are hg18 and hg19. This project used the hg19 
build and compared variants using dbSNP138, NHLBI GO Exome Sequencing datasets of 
African Americans and European Americans, and all samples within the 1000 Genomes project 
from the April 2012 release. Minor allele frequencies can be set manually prior to filtration. The 
minor allele frequency (MAF) was set at 0.01 for each family but the CS-64 trio. Due to the large 
amount of variants found after genetic level filtration, the MAF for this trio was set at 0.005. 
Variants are then mapped using Refseq to determine where the variant lies within the genome, 
and can be excluded based on the user’s specifications.  
The final level of filtration is the knowledge level. KGGseq incorporates physical 
protein-protein interaction from the STRING database to determine which variants will be the 
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most deleterious based upon their function. KGGseq allows the user to input a set of candidate 
genes to determine if the gene containing the variant interacts within the pathway of the 
candidate. Another optional feature of the knowledge level filtration is the capability to input 
certain words that can be searched for in the NCBI PubMed database.  
An example of a KGGseq script and candidate gene list is shown in Figure 8. Exact 
scripts used for each family are shown in Appendix I. After all variants have been filtered, an 
annotated excel document is output that can be filtered further based upon the user’s 
specifications. For this project, the resulting excel document for each family was evaluated and 
prioritized. Variants were kept that fell into the classification of missense, frameshift, splicing 
errors, stoploss, and stopgain. This excluded synonymous, intronic, intergenic, ncRNA, and 
nonframeshift mutations. 
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java -Xms256m -Xmx1300m  
-jar ./kggseq/kggseq.jar  
--buildver hg19  
--resource ./resource  
--no-resource-check  
--no-lib-check  
--out ./Trio1  
--excel  
--vcf-file craSyn-Trio1.recode.vcf  
--ped-file craSyn.ped  
--genotype-filter 1,2,6  
--seq-qual 30  
--seq-mg 20  
--seq-sb -10  
--gty-qual 20  
--gty-qual 8  
--db-gene refgene  
--gene-feature-in 0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15 
--db-filter 
hg19_1kg201204,hg19_dbsnp138,hg19_ESP6500AA,hg19_ESP6500EA  
--rare-allele-freq 0.01 
--db-score dbnsfp  
--mendel-causing-predict all  
--genome-annot  
--omim-annot  
--candi-list 
ALX4,BBS9,BMP2,BMP3,BMP4,BMP7,C1QTNF3,CYP26B1,EFNA4,ENFB1,MAPK1,ERK2,
ERK1,ERF,FAM20C,FBN1,FGF2,FGF7,FGF8,FGF9,FGFR1,FGFR2,FGFR3,FREM1,GLI3,GP
C3,IGF1R,IGF2R,IGFB3,IGFBP1,IGFBP5,IL11RA,KRAS,LMX1B,LRIT3,MCPH1,MSX2,NE
LL1,ORC1,POR,RAB23,RBP4,RECQL4,RUNX2,SFRP4,SKI,SNAI1,SOX6,TCF3,TCF12,TCO
F1,TGFB3,TGFBR1,TGFBR2,TWIST1,TWISTNB,WDR35,VCAM1,ZIC3  
--ppi-annot-string  
--ppi-depth 1 
 
 
Figure 8. KGGSeq script used to filter each individuals vcf file. Filters changing between 
families are shown in the boxes.  
 
 
 
Each vcf-file and output name 
changed for each family  
Genotypes as follows:  
1: recessive, excludes heterozygous genotypes in affected subjects 
2: recessive and full penetrance –compound heterozygosity, excludes 
homozygous variants that are the same in affected and unaffected subjects 
3: dominant, excludes reference homozygous genotypes in affected subjects 
4: dominant with full penetrance causal mutations, excludes heterozygous 
variants that are the same in affected and unaffected subjects 
5: dominant without heterogeneity, excludes alternative homozygous genotypes 
in affected subjects 
6: full penetrance, excludes variants not shared in all affected subjects 
7: de novo, includes only variants where an affected subject has any non-
inherited alleles 
8: somatic mutations among matched tumor and non-tumor samples, includes 
only variants where tumor and non-tumor genotypes differ 
Gene Features:  
0: frameshift 9: UTR5’  
1: nonframeshift 10: UTR3’ 
2:  startloss 11: intronic 
3: stoploss 12: upstream 
4: stopgain 13: downstream 
5: splicing 14: ncRNA 
6: missense 15: intergenic 
7: synonymous 16: monomorphic 
8: exonic  17: unknown 
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Quality Control of Variant Calls 
 Once variants were identified via KGGseq filtering, further analysis was performed 
through the Integrated Genome Viewer (IGV) available from www.broadinstitute.org/igv/home. 
The IGV allows real time exploration and analysis of large-scale genomic datasets on standard 
desktop computers. Each individual’s genome (BAM file) was loaded into the software and 
compared to the USCS hg19 build. Candidate variants were localized by using the chromosome 
number and position from the KGGseq output. Variants were then compared between family 
member and determined whether there was enough evidence to further analyze the gene. IGV 
quality control is a check based to determine that each variant identified has an adequate amount 
of reads to support the mutation found through KGGseq. An example of the view from the IGV 
is shown in Figure 9. 
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Figure 9. View of a BHMT variant in the IGV. View in the top left shows the genome build, chromosome number, and specific 
location on the chromosome. Along the left side are the names of the individuals being analyzed. Along the bottom of the figure are 
the sequence and the corresponding amino acid according to the RefSeq database. Hovering above the specific base will allow more 
information to be seen, as shown in the tan box. 
34 
 
Table 3 
PCR Primer Design 
 Primers for PCR and Sanger Sequencing of each gene were designed using the aid of IDT 
Primer Quest (http://www.idtdna.com/Primerquest/Home/Index) and ordered via IDT using 
Custom DNA Oligo Service. The Thermo Scientific Phire Hot Start II DNA Polymerase was 
used for all PCR reactions. Primers, annealing temperatures, and product sizes for each gene are 
shown in Table 1. PCR conditions were as follows: 94º C 1.5 min, (94º C 30 sec, annealing temp 
30 sec, 72º C 30 sec) x29, 72º C 7 min. PCR products were run on 6% acrylamide (19:1) and 
10% glycerol gels in 0.5X TBE and visualized using ethidium bromide as a staining agent. As 
shown in Table 3, a reverse primer was unable to be obtained for FGFR3. Four different primer 
sequences were attempted. For the FGFR3 forward sequencing, a primer was used that amplified 
inside the PCR product. This primer sequence was: GCAGCCGAGGAGGAGCTGGTGG 
Gene  Forward Primer 5 -> 3' Reverse Primer 5 -> 3' Temp Size 
BHMT TCCTGATGAAGAGAGGAGAGCTG GACAGAAACCAGGGACAAGAC 64 400 
C11orf34 GCACTGGAGAAGGGTTGATTG TGTTTTGGTCTGAAGCCGTG 60 472 
CCT4 AGTTAGCAGGTTATTCAAGCCAC ACAGTTACCTAGCCACTCTTG 67 421 
FGFR2 GGGGGTATCCTCTGGTTGCT ATGGCTACAGAGAAGAGAGAGC 60 511 
PTPN7 AGCCTTGGGTTCTTTGTGGG GCCCTCTTATATCCCCGGAGT 60 475 
RNF157 AGCAGGATCTACAGTGTGTGA GGAACAGCCCAGAGGGTTAC 60 537 
TRDN ACTTGTGACTTACCTTTCTTCCC GATGCTACCTCCAAACCCCTT 60 554 
TSPG1 TCAAAGCCTGTCGTGTGGAT ATCCAGTTCACGTAGGCAGG 64 551 
ZNF516 CAGGTCAGGGGGTCTTCGC CCACCACGTCTTGTTCTGACA 65 502 
FGFR3 ACGGACGGGAATCCTGTGA CTACATGGTGAAGCAGAGACGA  60 480 
BAMBI CTAGGAGGAGTTAGCATGGAG CTTCAAGCTGTTCAGTAAGTG 60 508 
CRELD1 GGTCGCTGTAAGAAGTGTAG CCTGGAAGGTATAAGGCTGC 60 588 
ITGAV GTAACCCTGAACTTGCCTTAT GTGCCTATGAGCTCCCTATTC 65 685 
SLC20A1 CTCCTTGTCCAAACAGTCTC GCTCTGTCAAACGGCTCTTC 60 624 
SLC30A9 GGTTATAACACAACCTGCTTC GATATGTAAGAGCCACACAGG 60 524 
AR GCCAAGCTCAAGGATGGAAG CCTCGCTCAGGATGTCTTTA 60 710 
HRNR CATCACTCTCTTGCTACATGG CTCTCACCAAGTAAGGACAATC 60 461 
FREM1 Ex15 CTGTCTTCAGGGGTCATGGAA CTGACCCGTTGAGTGTGTTA 60 405 
FREM1 Ex26 GCAAGATCTGCCCTTGATT CCTTGGTTTGTCCCATCTG 60 502 
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Sanger Sequencing  
 PCR volumes for Sanger Sequencing were cleaned using ZymoResearch DNA Clean and 
Concentrator. All Sanger sequencing reactions were performed by the MCV-VCU Nucleic Acids 
Research Facility using the BigDye Terminator v3.1 mix and the primers shown in Table 1. 
Results were viewed using Chromas Lite 2.1.1. 
In Silico Functional Prediction of Candidate Genes 
 Analysis of the candidate variants within the CS-64 family was performed using the aid 
of Project HOPE, run by Netherlands Bioinformatics Centre (www.cmbi.ru.nl/hope). Project 
HOPE uses Basic Local Alignment Search Tool (BLAST) to search the Uniprot database and the 
Protein Data Bank (PBD). PBD is used to find the 3D structure of the protein of interest, or a 
possible template for homology modeling. Multiple other programs are integrated into Project 
HOPE to build the structure of the protein, determine the domains and motifs within each 
structure, and analyze any known variants within the sequence. This information is then 
combined to analyze the effect of certain mutations on the protein structure and stability.  
CRISPR/Cas9 Clone Generation 
 CRISPR targets and sequencing primers for the targets were obtained using the aid of 
https://chopchop.rc.fas.harvard.edu/. CRISPR guide RNAs (gRNA) were designed according to 
the protocol “short oligo method to generate gRNA” taken from Talbot and Amacher (2013). 
Three gRNAs were designed for each candidate knockdown gene (SLC30A9 Guides 1, 2, and 3, 
and ITGAV Guides 1, 2, and 3) due to the known approximate 50% success rate of CRISPR 
guides. Each guide RNA included a clamp, T7 promoter, target sequence, and an overlap with 
the guide constant oligo. All gRNA, gRNA Primer 1, gRNA Primer 2, and guide constant oligo 
were obtained through IDT. Primer sequences are show in Table 4 a and b.  
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Table 4a 
Table 4b 
PCR amplification of template oligos was performed using the protocol from Talbot and 
Amacher (2013). The PCR was run with 1x Thermopol buffer, 0.25 μM each gRNA Primers 1 
and 2, 0.02 μM short-guide oligo, 0.02μM guide constant oligo, 3% DMSO, 0.2 mM dNTPs, and 
1.5 units Phire Hotstart II DNA Polymerase. Two 50μl reactions were run with the following 
cycling parameters: 95º C 1 min (95º C 15 sec, 60º C 30 sec, 72º C 20 sec) x40, 72º C 5 min. 
PCR amplified products were confirmed by visualization of a 120 bp band run on a  6% 
acrylamide (19:1) and 10% glycerol gels in 0.5X TBE using ethidium bromide as a staining 
agent 
Transcription of the gRNA was carried out via Ambion MEGAScript Sp6/T7 kit, 
following the manufacturer’s instructions, then cleaned using the MirVana miRNA Isolation Kit. 
The final concentration for each gRNA was diluted to 200 ng/μl for injections.  
 
 
 
 
 
 
Table 4 Key:Red color denotes the clamp, blue is the T7 promoter, black is the target sequence, 
and green is the overlap with the guide constant, as well as the sequence on the guide constant 
that overlaps.  
Name Sequence 
SLC30A9 Guide1 GCGTAATACGACTCACTATAGGTGCAGGTAGACCCGGCAGGTTTTAGAGCTAGAAATAGC 
SLC30A9 Guide2 GCGTAATACGACTCACTATAGGCAGGTATCAGCCAACGAGGTTTTAGAGCTAGAAATAGC 
SLC30A9 Guide3 GCGTAATACGACTCACTATAGGAGGACTGACCTGACAGCGGTTTTAGAGCTAGAAATAGC 
ITGAV Guide1 GCGTAATACGACTCACTATAGGCCCCAGAGGAACGCACAGGTTTTAGAGCTAGAAATAGC 
ITGAV Guide2 GCGTAATACGACTCACTATAGGGGCTCAGATGGCAAACTGGTTTTAGAGCTAGAAATAGC 
ITGAV Guide3 GCGTAATACGACTCACTATAGGTTCATCGCAGAGACCTGGGTTTTAGAGCTAGAAATAGC 
Guide Constant Oligo AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACG 
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC 
gRNA Primer 1  GCGTAATACGACTCACTATAG 
gRNA Primer 2 AAAGCACCGACTCGGTGCCAC 
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Generation of BAMBI Overexpression Clone  
 Zebrafish have two orthologues for the BMP and activin membrane-bound inhibitor 
(BAMBI) gene (orthologues a and b). Although little is known about the Bambi genes in 
zebrafish, it is thought that the two orthologues perform the same function with slightly different 
amino acid sequences. Bambia was chosen for overexpression studies due to its commercial 
availability. The cDNA clone of the Bambia gene in pBluescript SK- was ordered through 
http://dharmacon.gelifesciences.com (Appendix II). After arrival of the BAMBIa vector glycerol 
stock, the bacteria was streaked on an Ampicillin (Amp) Luria broth (LB) plate and grown 
overnight at 37º C. A 4 ml LB with 0.2 mg/ml Ampicillin overnight was prepared and shaken 
overnight at 225 rpm and 37º C. After ensuring bacterial growth had occurred, the Thermo 
Scientific GeneJET Plasmid Miniprep Kit was used to isolate the DNA.  
 A heat shock promoter vector (pCSHSP) was obtained from Dr. James Lister (Appendix 
II). Both vectors (pCSHSP and BAMBIa) were digested in a 50 μl reaction using 50 units of 
BamH1 20 u/μl (Appendix II), 1x New England Biolabs (NEB) Buffer 3.1, and 5 μg of DNA. 
The digest was incubated at 37º C for 1 hour. Confirmation of the digest was visualized on a 1% 
agarose gel run in 1X TAE using ethidium bromide as a staining agent. After complete digestion 
was confirmed, the rest of the samples were run on a 1% agarose prep gel. The band containing 
the BAMBIa insert and the cut pCSHSP vector were excised and purified using the BioRad 
Freeze N’ Squeeze DNA Gel Extraction Spin Column. Dephosphorylation of pCSHSP was 
performed in a 32 μl reaction using 1 unit/pmol Roche Shrimp Alkaline Phosphatase (SAP), 1x 
SAP buffer, and 1.36 μg of DNA. The reaction was incubated at 37º C for 10 min, then 65º C for 
15 min. The pCSHSP dephosphorylated vector and the BAMBIa insert were then ligated in a 10 
μl reaction using NEB 40 units of T4 ligase, 1x NEB T4 ligase buffer, and a 3:1 ratio of 
insert:vector with 50 ng of vector. The ligation reaction was incubated overnight at 14-15º C. A 
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control without the BAMBIa insert was ligated to determine the effectiveness of the 
dephosphorylation step.  
 Transformation into DH5α cells was performed as follows. Fifty microliters of 
supercompetant cells were gently thawed on ice and aliquoted into 50 μl tubes. Two microliters 
of the ligation reaction was added and mixed gently by tapping the tube. Cells were incubated on 
ice for 30 min, heat shocked for 40 seconds at 42º C, then placed on ice for 2 min. Nine hundred 
fifty microliters of room temperature LB was added to the 50 μl transformation mix and shaken 
at 225 rpm and 37º C for 1 hour. A volume of 100 μl of transformation mix was spread on an LB 
Amp plate to grow overnight at 37º C. Ten colonies were individually isolated and 2 ml 
overnights in LB and 0.2 mg/ml Amp were grown overnight at 225 rpm and 37º C. The plasmid 
DNA from each overnight was isolated using the Thermo Scientific GeneJET Plasmid Miniprep 
Kit, as above. A small amount (5 μl) of each plasmid was digested with BamH1 and run on a 1% 
agarose gel to identify if the correct insert had been cloned.  Three plasmids with the correct 
insert size were sent for sequencing using the SP6 primer to ensure the cloned DNA was in the 
proper orientation with no mutations. 
Zebrafish Culture and Maintenance  
 Adult fish were maintained at approximately 28°C on a 14 hour/10 light/dark cycle. Wild 
type strains (AB/ WIK or ZIRC AB) were used for all experiments unless otherwise indicated. 
Embryos were incubated at 28°C and staged according to Kimmel et al. (1995). 
Zebrafish Injection 
 Injection trays were made using 0.45 g agarose and mixed with 30 mls of system water. 
The mixture was microwaved for 1 min to melt the agarose and then cooled at room temperature 
for 10 min. Thirty microliters of methylene blue solution was added and then the mixture was 
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poured into a 10 cm petri dish. The injection tray mold was set on top of the fluid while 
solidifying. Injection trays are stored at 4º C until needed. Injection needles are created using the 
Sutter P-97 Flaming/Brown micropipette puller on program 6.  
Zebrafish males and females were separated into spawning tanks the evening before 
injections were to be performed. The morning of injections, fish are placed in a new spawning 
cage with fresh water and the divider is pulled out, allowing the males and females to mate. 
Injections were performed within 10 min of fertilization of the eggs. Approximately 40 embryos 
were injected for each target, aside from the control where 80 embryos were injected. Control 
fish were injected with only a the CRISPR protein. A mixture of 200 ng/μl of each CRISPR was 
mixed with 200 ng/μl of the Cas9 protein, to have a final concentration of 100 ng/μl of each 
vector. Each embryo was injected with approximately 1 nl of the mixture.  
Staining  
 Staining of the zebrafish was performed via the Clearing and Staining for Larval Fish 
Cartilage and Bone protocol from ZFIN (Potthoff, et al. 1984). Fish were stained at 5 weeks and 
8 weeks old. Once fish had reached the desired age, they were euthanized with Ethyl 3-
aminobenzoate, methanesulfonic acid salt 98% (MESAB), then fixed in 4% paraformaldehyde in 
PBS for 48 hours at 4º C. After fixation, fish were rinsed in two separate 5 minute PBS washes, 
dehydrated in 50% EtOH for 24 hours, then in 100% EtOH for 24 hours. Cartilage staining then 
proceeded with a 24 hour room temperature incubation with mild agitation in a 100 ml solution 
of 70% EtOH, 30% acetic acid, and 0.2 mg/ml Alcian blue. Fish were then neutralized in a 
saturated sodium borate solution for 9-12 hours and bleached for 20 min in a 100 ml solution of 
15% 3% hydrogen peroxide and 85% 1% potassium hydroxide. A trypsin digest followed 
involving a mild agitation wash in 35 ml saturated sodium borate, 65 ml ddH2O, and 1 g trypsin 
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until the specimens were 60% clear. Bone staining then proceeded with a 24 hour room 
temperature incubation with mild agitation in 1% potassium hydroxide and 1 μg/ml Alizarin red. 
Another trypsin digest then occurs for 40-48 hours. Preservation, the final step, proceeds at room 
temperature with a solution containing 30% glycerol and 70% 1% potassium hydroxide for 2-3 
days with mild agitation, then a solution of 60% glycerol and 40 % 1% potassium hydroxide for 
2-3 days with mild agitation, and finally a 100% glycerol solution.  
Genotyping 
 In order to identify mutation carries, DNA was prepared from fin clip biopsies and 
genotyped using PCR and Sanger Sequencing. PCR primers for the ITGAV Guide 1 and 
SLC30A9 Guide 3 are shown in Table 5. The other two ITGAV guide PCR primers ordered 
were not working properly and need to be redesigned. Once fish had reached the proper time 
points, listed above, and euthanized for staining, a triangular portion of the caudal (tail) fin 
measuring approximately 5mm on each side was clipped off using a clean razor blade. Using 
sterile forceps, this fin biopsy was place in 50 μl ZIRC lysis buffer (1.5 mM MgCl2, 10 mM Tris-
HCl pH = 8.3, 50 mM KCl, 0.3% Tween-20, 0.3% NP-40 (20%) in water). DNA was prepared 
by heating the samples in heat blocks through the following steps: 10 minutes at 95°C, followed 
by addition of 5 μl Proteinase K (10 mg/ml), followed by incubation at 55° C for 1 hour, and a 
final incubation at 95° C for 10 minutes to inactivate the Proteinase K. The tubes were then spun 
in a microcentrifuge and stored at -20° C 
 
Table 5. PCR Primers for Sanger Sequencing of CRISPR/Cas9 Mutants  
 Forward Primer Reverse Primer 
ITGAV Guide 1 GATGACAGAAAGCATTCCAATG GCAGATGTTTTTATTCAGGT 
SLC30A9 Guide 3 CTGCGTTTCTCATCTACACC GCTTGTTGGCTGATTAAGC 
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Chapter 3: Results 
Whole Exome Sequencing Analysis  
 Sequencing of all exomes from Beckman Coulter Genomics, Inc was completed with an 
average forward quality Phred score of 36.2 and an average reverse quality Phred score of 35.8. 
Exome and targeted region coverage details are shown in Table 6. Forward and reverse strand 
statistics refer to the exome. Target capture bait design is strand biased and target capture is 
strand specific. Reverse reads are, in general, of lower quality than the forward reads and as a 
result, there will be some strand bias. Most variant callers will filter out detected variants if 
observed on only one strand. The ‘proper’ pairs reported are read pairs mapped at expected 
distance and orientation, with regards to library size. Lastly, the on-target percentage reflects the 
proportion of reads overlapping the baits. Since, for instance, for exome design, over two 
hundred thousand regions are targeted, quite often, one of the two reads in a pair will be off 
target. Table 7 shows average coverage per sample, as well as proportions of the bait regions, 
having at least 5X and at least 10X coverage.  
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Table 6. WES Statistics  
 
 
 
 
 
 
 
 
 
 
 
 Reads  
Generated 
GC Reads  
Mapped 
Prop. 
Mapped 
On  
Target 
F 
Strand 
R 
Strand 
Strand 
Bias 
Pairs 
Mapped 
Proper 
Pairs 
Single- 
tons 
CS-14 84,371,026 45% 83,140,241 98.5% 64% 50.5% 49.5% 1% 98.1% 97.5% 0.5% 
 
CS-15 73,436,098 46% 72,540,492 98.8% 66.6% 50.4% 49.6% 0.8% 98.4% 98% 0.4% 
CS-39 98,934,296 45% 97,629,084 98.7% 66.7% 50.4% 49.6% 0.9% 98.3% 97.8% 0.4% 
CS-54 89,719,978 46% 88,596,749 98.7% 70.3% 50.4% 49.6% 0.8% 98.3% 97.9% 0.4% 
CS-55 90,868,512 47% 89,680,185 98.7% 68.1% 50.4% 49.6% 0.9% 98.3% 97.8% 0.4% 
CS-58 89,545,620 46% 88,429,99 98.8% 66.1% 50.4% 49.6% 0.8% 98.3% 97.9% 0.4% 
CS-59 89,952,862 47% 88,767,038 98.7% 69.6% 50.4% 49.6% 0.8% 98.2% 97.5% 0.5% 
CS-60 87,584,168 47% 86,390,970 98.6% 67.3% 50.5% 49.5% 0.9% 98.2% 97.7% 0.4% 
CS-61 83,960,342 46% 82,865419 
 
98.7% 67.3% 50.4% 49.6% 0.9% 98.3% 97.7% 0.4% 
CS-64 83,774,682 47% 82,629,412 98.6% 67.1% 50.4% 49.6% 0.9% 98.2% 97.6% 0.5% 
CS-65 97,185,868 47% 95.713,982 98.5% 69.8% 50.5% 49.5% 1% 98% 97.5% 0.5% 
CS-66 88.768,752 45% 87,434,774 98.5% 62.7% 50.5% 49.5% 1% 98% 97.3% 0.5% 
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Table 7. WES Average Coverage  
 
 
 Library Read Pairs Avg.Cov. >5X >10X PicardDupl. SamtoolsDupl. FastQCDupl. MedianCov. Pairs Needed 
CS-14 IL7221 28,792,928 92.1X 97.6% 96.4% 9.6% 9.5% 25.5% 77.5X 2,469,752 
CS-15 IL7222 30.141,652 83.6X 98.1% 96.8% 9.2% 9.1% 27.7% 71.6X 5,912,956 
CS-39 IL7229 34.159,444 112.8X 97.7% 96.7% 15.4% 15.2% 33.5% 97.2X 0 
CS-54 IL7230 30,822,168 108X 98.4% 97.5% 24% 23.8% 41.5% 93.4X 1,086,340 
CS-55 IL7223 29,398,810 106.3X 98.8% 98% 12.8% 12.7% 28.8% 93.7X 0 
CS-58 IL7224 29.510,856 101.2X 98.7% 97.8% 15.1% 15% 30.4% 87.6X 0 
CS-59 IL7231 34,523,270 107.4X 98.9% 98.2% 13.5% 13.4% 33.6% 95X 0 
CS-60 IL7225 23,623,880 101.1X 98.8% 98% 14% 13.9% 26.4% 89.1X 0 
CS-61 IL7226 34,064,086 96.6X 98.3% 97.4% 14.2% 14.1% 33.8% 84.6X 1,198,943 
CS-64 IL7227 31,934,591 96.1X 98.1% 97.2% 19.6% 19.4% 38.5% 85.9X 3,180,692 
CS-65 IL7232 25,621,162 116.2X 99% 98.3% 14.6% 14.4% 27.8% 101.5X 0 
CS-66 IL7228 30.707,133 95.2% 97% 95.8% 11.8% 11.7% 27.3% 83X 1,548,259 
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Mendelian Error Analysis 
Results from the Mendelian error analysis are shown in Table 8. Errors from the analysis 
with the real pedigree file are shown in column two and the mean of the three simulation trials is 
shown in column three. Column four shows the p-value corresponding to the one tailed t-test. 
There are many more errors in the pedigrees when the parent genotypes have been simulated and 
there are significant differences between the real and simulated pedigrees.  
For the CS-14 twin pair, 43 errors were found in non-intergenic and non-intronic areas of 
the exome sequencing. This makes up less than 0.001% of the exome sequencing performed.  
 
 
 
 
 
 
 
 
 
 
 
Table 8. Mendel Errors 
 Mendel Errors 
Real pedigree 
Mendel Errors 
Mean of 3 Simulations 
p-value 
One tailed t-test 
CS-39 Trio 344435 509325 0.000144 
CS-64 Trio 302148 431749 0.005361 
CS-58 3 Generation 393672 637592 0.0092 
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KGGSeq and IGV Filtering 
Analysis of the WES performed involved two main steps: KGGseq filtering and IGV 
quality control analysis. For the three generation CS-58 family, 113 variants were left after 
dominant KGG filtering. Mutations with no rsID were eliminated in order to narrow the search to 
novel mutations not yet identified, leaving 29 variants left. Further filtering kept only variants 
with a SIFT score of less than 0.5, as well as a Polyphen2_HDIV score greater than 0.957, 
leaving 15 total. These two tests were used to determine which variants are predicted to be the 
most deleterious. Twelve were kept after IGV analysis. The most significant variant identified 
was a missense mutation in the FGFR2 gene. According to RefSeq records, the mutation is 
located within exon 2 of NM_1144913, NM_1144917, and NM_1144914; and exon 3 of 
NM_00141 and NM_22970. Within each of these alternate sequences, an A314G mutation is 
seen. This corresponds to a Y105C amino change. The other eleven genes in which variants were 
found included MASP2, PTPN7, CCT4, ANKMY1, BHMT, TRDN, CIZ1, OR6T1, RNF157, 
and ZNF516. These mutations were included in further confirmatory tests in order to determine 
the efficiency of the WES.  
 For the CS-39 trio, de novo KGG filtering found 6 variants, and recessive filtering left 3 
variants. After viewing each variant through IGV, 4 de novo and 2 recessive alleles remained. 
The most significant candidate variant was a de novo FGFR3 missense mutation. According to 
RefSeq records, the mutation is found in exon 9 of NM_00142 and NM_1163213. This mutation 
is C1172A, corresponding to A391E amino acidchange. 
 Filtering of the variants from the monozygotic twins, CS-14 and CS-15, left 7 variants. 
IGV analysis left two candidate genes, androgen receptor (AR) and hornerin (HRNR). The AR 
mutation is an A173T change found within exon 1 of RefSeq NM_000044, corresponding to a 
Q58L change. The HRNR mutation is found within exon 2 of RefSeq NM_001009931 causing 
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an A1T mutation, resulting in a M1L change. The twins were then filtered to determine if there 
were any mutations in both of their exomes that are known to cause craniosynostosis. No such 
variants were found.  
 Within the CS-64 trio, 143 variants were found after KGG filtering. In order to narrow 
down the candidate genes, variants with no rsID were kept in order to narrow the search to novel 
mutations not yet identified, dropping the number to 40. Further filtering included only variants 
with a SIFT score of less than 0.5 and a Polyphen2_HDIV score greater than 0.957. As with the 
CS-58 family, these two tests predict how deleterious the mutation is predicted to be. In the end, 
only 26 genes were left. Each of the 26 genes were analyzed to determine function and known 
embryonic tissue localization. Three variants, integrin alpha V (ITGAV) BAMBI, and solute 
carrier family 30, member 9 (SLC30A9), were left after analysis. Two additional variants were 
included in sequencing: SLC20A1 and CRELD1.  
ITGAV has a missense mutation in exon 2 of NM_1144999, NM_1145000, and 
NM_002210. In NM_1144999, the mutation occurs at base 61. In the other two sequences, the 
mutation is at base 199. The mutation changes a cytosine to a thymine, leading to a leucine to 
phenylalanine change in the protein at amino acid 21 or 67, depending on the transcript. 
SLC30A9 has a missense mutation in exon 13 of RefSeq record NM_006345 causing C1079T, 
corresponding to a L360P change. The BAMBI gene has a mutation in exon 3 of RefSeq 
NM_012342 of A368G, leading to an M190V mutation.   
 Within the CS-2 six member family, 375 variants were found after KGG filtering. 
Further filtering included only variants with a SIFT score less than 0.5 and a Polyphen2_HDIV 
score greater than 0.975, narrowing the number to 84. The most interesting candidate was the 
FREM1 gene due to its known involvement in craniosynostosis. Two candidate variants were 
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identified in separate exons. The first variant is within exon 15 of RefSeq record NM_144966, 
causing a C2408A mutation. This corresponds to an S803W amino acid change. The second 
mutation is within exon 26 of RefSeq record NM_144966. This mutation is a G4504A change , 
corresponding to a V1502M amino acid change.  
A list of all candidate genes identified, as well as the amount of variants left after each 
step is shown in Table 9 a and b. Detailed results from all families are shown in Appendix I.  
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Table 9a. Variants Left After Filtering Steps 
 CS-58  
(3 Generation) 
CS-39 
 (de novo Trio) 
CS-14  
(MZ Twins) 
CS-64 
(Dominant Trio) 
CS-2 
(Recessive 
Family) 
KGG and Excel 
Filtering 
113 9 7 143 375 
No rsID 29 - - 40 - 
SIFT < 0.5 and 
Polyphen_HDIV 
> 0.957 
15 - - 26 84 
IGV Analysis 12 6 2 26 - 
Functional 
Prediction 
- - - 3 2 
 
 
Table 9b. Candidate Genes for Each Family (* = Kept solely for sequencing) 
CS-58 CS-39 CS-14 CS-64 CS-2 
FGFR2 
 
* 
FGFR3 HRNR 
AR 
ITGAV 
SLC30A9 
BAMBI 
FREM1 Ex15 
FREM1 Ex26 
MASP2     
PTPN7   *  
CCT4   CRELD1  
ANKMY7   SLC20A1  
TRDN     
CIZ1     
BHMT     
OR6T1     
TSPG1     
RNF157     
ZNF516     
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Sanger Sequencing  
 Sequencing confirmed all variants within the CS-58 aside from ANKMY1, MASP2, and 
OR6T1. Successful primer sets to amplify these three genes were unable to be found and were 
not pursued. Sanger sequencing was also able to confirm the three CS-64 family variants and the 
FGFR3 mutation in the CS-39 family. Both variants within the CS-14 affected individual were 
shown to be unconfirmed. Within the six member CS-2 family, the mutation in FREM1 exon 15 
was confirmed to be heterozygous in CS-2, CS-3, CS-5, homozygous alternate in CS-4, CS-6, 
CS-7. The FREM1 exon 26 mutation was confirmed to be homozygous reference in CS-2, 
homozygous alternate in CS-7, and heterozygous in all four of the children: CS-3, CS-4, CS-5, 
and CS-6.  
 A total of 70 samples were sent for Sanger Sequencing. This included 9 variants from the 
CS-58 family, 1 variant from the CS-39 trio, 5 variants from the CS-64 trio, 2 variants from the 
CS-14 twins, and 2 variants from the six member CS-2 family. Of these 70 samples, only the 2 
from the affected CS-14 twin were shown to not be confirmed. The call made from Beckman 
Coulter Genomics, Inc. could have been wrong due to a low sequence quality or read depth.  
CS-64 Candidate Gene Analysis 
 Once sequencing confirmed the three candidate mutations, each gene was analyzed in 
order to determine the effect of each mutation on the corresponding protein. The leucine to 
phenylalanine mutation in ITGAV occurs within a stretch of repeats called the “FG-GAP 1”. FG-
GAP repeats are found in the N terminus of integrin alpha chains, a region that is important for 
ligand binding. The mutation is predicted to disrupt the repeat. Based upon conservation and 
amino acid properties, this mutation is predicted to be damaging to the protein, decreasing the 
stability.  
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 The leucine to proline mutation in SLC30A9 is located within a stretch of amino acids 
annotated in the Uniprot database as a transmembrane domain. This transmembrane domain is 
predicted to be part of a zinc transporter. Because the mutant is smaller and more rigid than the 
wild-type residue, interactions between amino acids, as well as flexibility of the chain can be 
disrupted. Due to the possible disruption of the transmembrane function, this mutation is thought 
to be damaging to the protein and decrease the stability.  
 Not much is known about the methionine to valine mutation in BAMBI, except that it is 
located in a conserved domain. However, few other residues have been observed in the same 
position. Although valine is not one of these few, residues with similar properties have been 
observed in this position. This leads to the possibility that this mutation may increase the stability 
of the protein.   
Functional Analysis of CS-64 Candidate Genes 
 After variants for the CS-64 family had been narrowed down through functional 
prediction and protein stability prediction, it was determined that two of the genes, ITGAV and 
SLC30A9 were candidate genes for knockdown studies. The other variant, BAMBI, was a 
candidate for overexpression studies. Knockdown studies were performed using a CRISPR/Cas9 
method. The overexpression study was performed using a sub cloning method with a heat shock 
promoter vector.  
At the 5-week time-point for the CRISPR/Cas9 injections, 5 of the zebrafish knockdown 
strains still had surviving individuals left out of the approximately 40 per line that were injected. 
All fish in the SLC30A9 Guide 2 knockdown line had died. Within the SLC30A9 Guide 1, 2 fish 
were surviving, so none were taken for staining at this 5 week time-point. The SLC30A9 Guide 3 
line had 9 surviving fish, so 3 were taken for staining. Of the ITGAV lines, Guide 1 had 5 fish, 
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Guide 2 had 9 fish, and Guide 3 had 28 fish. Of these lines, 2 were taken for staining from the 
Guide 1 line, 3 were taken from the Guide 2 line, and 5 were taken from the Guide 3 line. There 
were 18 living control fish, so 3 were taken for staining. Results of the staining are shown in 
Figure 10. All fish within each gene group were similar in appearance, so a representative 
pictures is shown.  
 At the 8-week time-point for the CRISPR/Cas9 injections, 4 of the zebrafish knockdown 
strains still had surviving individuals. In addition to the previous expiration of the SLC30A9 
Guide 2 knockdown fish, the SLC30A9 Guide 1 knockdown line had no surviving fish. The 
SLC309 Guide 3 strain had 6 surviving fish and all were taken for staining. Of the ITGAV 
knockdown lines, all 3 remaining fish from the Guide 1 line were taken, all 6 of the remaining 
fish of Guide 2 were taken, and 11 were taken from the surviving 23 of Guide 3. Of the control 
individuals, 5 were taken for staining. Staining results for the 8-week time-point are pending.  
Table 10 shows the amount of each strain left at each time point.  
 
 
 
 
 
 
 
 
 
 
52 
 
 
 
 
 
 
 
Figure 10. Staining results from 5-week time-point. Blue indicates cartilage and purple indicates 
bone. (A) Control fish. (B) ITGAV Guide 1 Knockdown. (C) SLC30A9 Guide 3 knockdown.  
 
 
Table 10. Fish Left at Each Timepoint  
 ITGAV 
Guide 1 
ITGAV 
Guide 2 
ITGAV 
Guide 3 
SLC30A9 
Guide 1 
SLC30A9 
Guide 2 
SLC30A9 
Guide 3 
Control 
Initially Injected  ~40 ~40 ~40 ~40 ~40 ~40 ~80 
Left at 5 weeks 5 9 28 2 0 9 38 
Taken for staining at 5 
weeks 
2 3 5 0 0 3 3 
Left after 5 week staining 3 6 24 2 0 6 35 
Alive at 8 weeks 3 6 24 0 0 6 28 
Taken for staining at 8 
weeks 
3 6 11 0 0 6 5 
 
A 
B C 
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BAMBIa Cloning  
Results for the BAMBIa overexpression are pending secondary to germline transmission. 
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Chapter 4: Discussion 
 It was of interest in this study to analyze both syndromic and nonsyndromic 
craniosynostosis patients in order to determine whether any candidate mutations could be 
identified. We had two syndromic families, one affected with Crouzon syndrome and one with 
Pfeiffer Type 3. Analysis of their exomes resulted in the identification of FGFR mutations, genes 
known to cause certain craniosynostosis syndromes. However, their phenotypes do not fit the 
reported phenotypes caused by their specific mutations, leading to an expansion for the 
phenotypical features caused by the mutation. The identification of several candidate genes in the 
nonsyndromic families opens up a direction for future research into the causes of NSC.  
Mendelian Error Analysis 
Although a significance difference was found when comparing the Mendelian errors of 
the proper family pedigree and the mean of the three simulations, there was still an excess 
amount of errors as compared with previous studies. Previous studies have shown an average of 
3-5% of Mendelian errors found within a trio family (Patel, et al 2014 and O’Roak, et al 2012). 
Our variant findings make up approximately 6-7% of the sequence captured by sequencing. This 
can be explained, at least in part, by the method Beckman Coulter Genomics, Inc used for calling 
variants. They called variants beginning at the bases immediately following the primers as well 
as sequences adjacent but outside the exome capture areas. This can lead to a large amount of 
variants called due to low sequence quality at the areas directly flanking the primers. In addition, 
regions not part of, but adjacent to the capture regions have very low sequencing depth so calls 
are not accurate in these areas.   
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For the CS-14 twin pair, the small percentage of less than 0.001% of variants confirms 
the monozygotic nature of their relationship based upon comparison with previous studies 
(Chaiyasap, et al. 2014) (Peterson, et al, 2014).  
Confirmation with Sanger Sequencing  
 Sanger Sequencing was able to confirm the correct variant calls in 68 out of the 70 
samples sent for sequencing. The two unconfirmed sequences were the mutations expected in the 
CS-14 twin. These were both identified as heterozygous in CS-14 and homozygous for the 
reference allele in CS-15. However, upon Sanger Sequencing, the variants in CS-14 were shown 
to be homozygous for the reference allele. Reasons for this miscall could be that for the AR 
gene, there were only 13 reads total from CS-14, with 9 A (the reference allele) and 4 T (the 
mutant). For the HRNR variant, there as a deletion expected and it showed to be present in both 
twins. The CS-14  twin had 19 reads on this variant, and CS-15 had 22. Thus, the miscalls of 
these variants can be attributed to low sequence reads.  
FGFR3 Mutations CS-39  
 The FGFR3 A391E mutation found in the CS-39 family has previously been studied in 
cases of Crouzon syndrome with AN. This mutation was of specific interest in FGFR3 studies 
because almost all documented FGFR3 mutations are associated with dwarfism syndromes of 
differing severities: achondroplasia (ACH, most common form of human dwarfish), 
Thanatophoric dysplasia (TD, lethal), and hypochondroplasia (HCH, mild). The primary 
difference between the mutations seen in most FGFR3 regions and the mutation associated with 
Crouzon with AN is the location of this mutation within the transmembrane region. Most FGFR3 
mutations are found in the cytoplasmic tyrosine kinase domain, as well as in the third 
extracellular Ig-like domain (Figure 4). It has been shown that the A391E mutation stabilizes the 
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FGFR3 transmembrane domain homodimer in lipid bilayers, leading to over-stabilization of the 
FGFR3 dimers and increasing ligand-independent action. (Chen, et al. 2011).    
Crouzon syndrome is an autosomal dominant disorder characterized by bicoronal 
synostosis, lip or cleft palate, midface hypoplasia, beaked nose, proptosis, and occasionally 
hearing loss. Hands and feet in individuals with Crouzon syndrome are typically structurally 
normal. AN is a skin disorder characterized by dark, thick, velvety skin in body folds and creases  
 CS-39 was born with complex synostosis involving the metopic, bicoronal, and lambdoid 
sutures. She also presented with proptosis, a tense and bulging fontanelle, midface hypoplasia, 
subsquamosal bulging, noisy breathing with gurgling, Chiari malformation, and turricephaly 
with a coned superior occiput and flattened lower occiput. In addition to her craniofacial 
abnormalities, she struggled with delayed gastric emptying, seizures, and kyphosis of her lower 
thoracic/upper lumbar spine. Genetic screening was performed in order to test for TWIST1 
mutations, FGFR1 P252R mutation, FGFR3 P250R mutation, and sequencing of FGFR2 exons 
3a, 3c, 8, and 10. The FGFR1 P252R mutation is a known cause of Pfeiffer syndrome and the 
FGFR3 P250R mutation is a known cause of Muenke syndrome. She was tested for the Muenke 
syndrome mutation due to the overlapping phenotypical features between the craniosynostosis 
syndromes. All results revealed no mutations. Clinically, CS-39 was classified as having Pfeiffer 
syndrome type 3, a syndrome that presents with complex synostosis, midface hypoplasia, hearing 
loss, severe proptosis, short anterior cranial base, and dental problems.  Individuals with Pfeiffer 
syndrome also often have abnormalities in the hands and feet, such as syndactyly, bradydactyly, 
and an abnormally wide thumb and big toe that are bent away from other digits. Problems with 
the central nervous and gastrointestinal systems are common with these individuals (Hollier, 
2015). 
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As shown in Figure 4, there is one mutation on FGFR1 that is known to cause Pfeiffer 
syndrome, and multiple mutations on FGFR2. However, no known mutations on FGFR3 have 
been known to cause Pfeiffer syndrome (Chen, et al). Identification of this mutation in an 
individual classified as having Pfeiffer syndrome leads to the possibility of variable expressivity. 
As shown in Figure 4, several mutations on FGFR2 lead to either Crouzon or Pfeiffer syndrome. 
These syndromes present with an overlapping phenotype, although Pfeiffer syndrome seems to 
present in a more severe manner. This increase in severity is primarily evidenced by the 
abnormalities often seen in the hands and feet, as well as increased suture fusions in Pfeiffer 
syndrome. The identification of this variant in CS-39, a case differing greatly from the classic 
phenotype of individuals with Crouzon with AN, can be possibly explained by the presence of 
another variant within either individuals with Crouzon with AN, or our individual. This other 
variant could be within a modifier gene that could cause the dysregulation of another protein 
within the pathway of the FGFR3 protein. Additionally, there could be reduced penetrance 
associated with this mutation, where a less severe form is the only phenotype that has been 
classified since its identification.  
FGFR2 Mutation CS-58 Family  
The FGFR2 mutation found in the three generation CS-58 family has previously been 
studied in one case of an individual with what was classified as Crouzon syndrome. Of all the 
known FGFR2 mutations within all disease types, 94% are found in exon 8, exon 10, or the 
intron sequence flanking exon 10. The Y105C mutation is found in exon 3 within the first Ig-like 
domain of the receptor and has been identified as the only known mutation within this domain 
(Kan, et al. 2002). This mutation creates a cysteine residue next to another cysteine at position 
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107, leading to the possibility of ligand-independent activation due to disulfide bonding (Yu, et 
al. 2000).   
CS-58 presented with left coronal, left lambdoid, and squamous synostosis. He also had 
scalloping of the occipital bone and an unusually large anterior fontanelle. This patient had 
normal hearing, but low set ears. He showed no evidence of midface hypoplasia, but his palate 
was slightly arched and his left eye displayed ptosis with mild proptosis. This patient was 
diagnosed clinically as having atypical Crouzon based upon these findings and the absence of 
limb abnormalities. Prior to this study, genetic testing of CS-58 screened for FGFR3 mutations, 
with no mutations found.   
 Previously, the Y105C mutation has been identified in an individual with left coronal and 
sagittal synostosis, as well as moderate proptosis. This individual had normal limbs and digits, as 
well as normal development. Similar to CS-58, this patient was diagnosed with atypical Crouzon 
syndrome (Pulleyn, et al, 1997).  
Although the Y105C mutation has only been seen a handful of times, leading to an 
inability to fully study the range of phenotypic features associated with it, we can assume that 
this mutation contributes to Crouzon syndrome, primarily in an atypical fashion. However, the 
identification of additional individuals with this mutation would help clarify its clinical 
implications.  
FREM1 Mutations in CS-2 Family  
     Analysis of the two FREM1 mutations found in the six member CS-2 family revealed 
that the affected individuals (CS-3 and CS-4) have differing genotypes of the two variants. The 
affected individual CS-3 and unaffected individual CS-5 are both heterozygous for the variants 
in exon 15 and exon 26 and have the same genotype. Affected individual CS-4 and unaffected 
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individual CS-6 are both homozygous alternate for the variant in exon 15 and heterozygous for 
the variant in exon 26. Due to these findings, we can conclude that the FREM1 mutations are not 
likely, on their own, causative for the craniosynostosis phenotype found in this family. The 
FREM1 gene has been implicated in nonsyndromic metopic synostosis, but the two affected 
individuals in the CS-2 family are affected with sagittal synostosis. It is possible that the disease 
causing mutation is found within the exome sequencing that was performed, but further analysis 
is needed to narrow down candidate genes. There is also the possibility of the disease causing 
mutation being a combination of a FREM1 variant and another variant. Thus, further research 
into the FREM1 gene, as well as the results of the WES, is necessary to fully rule out this gene as 
causative for the craniosynostosis phenotype seen in CS-3 and CS-4. 
CS-14 Twin Pair 
 Due to the lack of mutations found in the WES of the CS-14 twin family, it can be 
reasonably assumed that the disease causing mutation is within a segment of DNA that is missed 
by exome sequencing. WES misses approximately 15% of mutations. Mutations excluded by 
WES include those found in mitochondrial DNA, noncoding RNA, triplet repeat expansions, 
uniparental disomy, copy number variants, epigenetic changes, and intronic changes. Control 
sequences, or genes that control and modify other genes, are also often missed in WES because 
approximately half of the approximately 1,000 microRNAs are intronic (Belkadi, et al. 2015). 
Further research with this twin pair may involve WGS in order to identify the disease causing 
mutation. It is unlikely that environmental factors during the mother’s pregnancy played a role, 
leaving a de novo genetic cause as the most likely reason for the discordance between the twins. 
The lack of identification of mutations within genes known to contribute to a craniosynostosis 
phenotype decreases the possibility of reduced penetrance. However, there could be a mutation 
60 
 
within a gene in both of the twins that has not yet been linked to craniosynostosis that presents 
with reduced penetrance, but this would require extensive testing on many different genes.  
CS-64 Family Candidate Genes 
 Mutations known to cause nonsyndromic craniosynostosis have not yet been clearly 
identified. Of the few that are known, FGFR3 P250R has been associated with isolated coronal 
synostosis, as well as Muenke syndrome. FREM1mutations have been found in association with 
nonsyndromic metopic craniosynostosis. Sagittal synostosis, the most common type of 
craniosynostosis, has not yet had any causative mutations identified. CS-64 was born with 
nonsyndromic sagittal synostosis. CS-65, the father of CS-64, presented with clinical features 
indicative of sagittal synostosis. Thus, the identification of a candidate mutation within this 
family could lead to the possibility of further research into a cause of scaphocephaly. Three 
candidate genes were identified through KGGseq and Sanger sequencing as possible disease 
causing mutations for nonsyndromic sagittal synostosis. Mutations were found in genes ITGAV, 
SLC30A9, and BAMBI. These genes are discussed below.  
ITGAV 
Integrins serve as receptors for extracellular matrix-mediated cell adhesion, migration, 
cytoskeletal organization, cell proliferation, survival, and differentiation. Integrins function as 
heterodimers involving an alpha and beta subunit. They dimerize and bind with a ligand in order 
to communicate to the cell the character of extracellular matrix that is bound. There are 24 α 
subunits and 9 β subunits, but increased diversity is achieved by alternative splicing of the 
integrin RNA. Ligand binding with integrins is dependent on extracellular Ca
2
 or Mg
2+
, 
depending on the integrin (Alberts, et al. 2002). 
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Interaction between an integrin and its ligand allows the cytoplasmic tail of the β subunit 
to bind a variety of intracellular anchor proteins, including talin, α-actinin, and filament. These 
anchor proteins can bind other anchor proteins such as actin or vinculin, thus linking the integrin 
to actin filaments in the cytoplasm. Signaling function depends on a cytoplasmic protein tyrosine 
kinase called the focal adhesion kinase (FAK). FAK is recruited to focal adhesions by talin, 
which binds to the β subunit; or paxillin, which binds to one type of α-integrin. Once multiple 
FAK molecules have clustered together, a phosphotyrosine docking site for members of the Src 
family of cytoplasmic tyrosine kinases is formed (Alberts, et al. 2002). Src then phosphorylates 
p130CAS and paxillin, which recruits the Crk-DOCK180 complex in order to activate Rac. Pac 
activates p21-activated kinase (PAK), Jun amino-terminal kinase (JNK), and nuclear factor B 
(NF- B). FAK can also activate extracellular signal-regulated kinase (ERK) and mitogen-
activated protein kinase (MAPK) by recruiting RAP1. RAP1 activates ERK/MAPK through B-
raf. FAK can also activate ERK/MAPK via growth factor bound 2 (GRB2) and son-of-sevenless 
(SOS) complex (Guo, et al. 2004) (Figure 11).  
ITGAV encodes the α-5 subunit of the integrin family and has been implicated in many 
developmental processes. Alpha-5 has been shown to heterodimerize with β-1, 3, 5, 6, and 8. The 
α-5 subunit primarily interacts with the RGD sequence in a variety of ligands, including 
vitronectin, fibronectin, osteopontin, bone sialoprotein, thrombospondin, fibrinogen, von 
Willebrand factor, tenascin, and agrin. Integrin α5β8 is known to bind with laminin and type IV 
collagen (Hamosh, 2011). Previous knockout studies have shown that ablation of the gene for the 
α-5 integrin, although primarily causing lethality, allows considerable development and 
organogenesis, including extensive vasculogenesis and angiogenesis. From this trial, 20% of 
mice survived, but had considerable defects, including cleft palates, intracerebral hemorrhages, 
62 
 
and intestinal hemorrhages (Bader, et al 1998). Conditional knockout studies in mice have shown 
that α-5 integrins are central to intestinal immune regulation. Integrin α5β6 has been shown to 
associate with TGF- β1 in the skin and lungs. Knockout studies have shown that blocking TGF-β 
or its activation could be an effective treatment against pulmonary edema in acute lung injury 
(Lacy-Hubert, et al 2007). 
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Figure 11. Integrin signaling pathway. Taken from Guo, et al. 2004 
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SLC30A9 
 SLC30A9 encodes member 9 from a family of several zinc transporters responsible for 
zinc homeostasis within the cell. Zinc is an essential element in organisms due to its function as a 
cofactor for hundreds of enzymes. Of the zinc transporter genes, SLC30 (ZnT) family genes are 
primarily responsible for facilitating removal of zinc from the cytosol, either out of the cell or 
into the lumen of vesicles or organelles. The SLC39 (ZIP) family of zinc transporters is 
responsible for the influx of zinc into the cytosol from either the outside of the cell or from the 
lumen of vesicles. These transporters are involved in several processes crucial to growth, 
development, reproduction, immunity, and bone formation (Cousins, et al. 2011). 
 Most members of the SLC30 family have 6 transmembrane domains and are predicted to 
have cytoplasmic amino and carboxy termini. Additionally, these proteins have a long histidine 
rich loop between transmembrane domains IV and V, the location where zinc is predicted to 
bind. With the exception of members 5 and 6, SLC30 members function as homodimers 
(Stephen, et al. 2012).  
 Inhibition of SLC30 family member 7 has shown increased osteogenic differentiation of 
mesenchymal stem cells. Overexpression of this same gene showed down regulation of beta-
catenin. Beta-catenin is known to interact with Wnt genes in order to play a major role in the 
differentiation of mesenchymal stem cells. Another member of the zinc transporter family was 
shown to attenuate osteogenesis by inhibiting activated MAPK/ERK pathway, a signaling 
pathway known to play a role in differentiation of mesenchymal stem cells (Liu, et al. 2013). Not 
much is known about SLC30A9, but it was of significance for further analysis in our study due 
to noteworthy interactions of the SLC30 family members.   
65 
 
BAMBI 
 The BAMBI gene encodes a pseudo receptor for TGF-β that leads to inhibition of the 
TGF-β signaling pathway. TGF-β molecules cause downstream signaling through receptors that 
function as serine-threonine kinases to phosphorylate Smad proteins. Smad proteins then 
translocate to the nucleus to regulate TGF-β gene transcription (Figure 12). BAMBI exhibits 
structural homology to TGF-β receptor 1, but lacks the intracellular kinase domain. In lacking 
this domain, the BAMBI receptor acts as an antagonist to TGF superfamily members. (Luo, et al. 
2012).  
 Not much is known about the physiological functions regulated by BAMBI, but it has 
been identified as a negative regulator of BMP during embryogenesis. However, studies have 
shown that knockouts of BAMBI show no phenotypic consequences during embryonic 
development. Mutant knockout mice were fertile, healthy, and displayed longevity that was 
comparable to wild-type littermates. BAMBI transcripts are abundantly seen in several CNS 
areas critical to pain processing, indicating a role for TGF-β in nociceptive regulation, both 
centrally and peripherally (Tramullas, et al. 2010). TGF-β is a multifunctional cytokine that 
controls proliferation, differentiation, migration, adhesion, and apoptosis of cells within the 
body. Blockage of TGF-β has been implicated in the progression of many carcinomas (Zhou, et 
al. 2013).  
BAMBI proteins can also function as positive regulators of the Wnt/β-catenin pathway. 
Zhou et al. examined the role of BAMBI in osteosarcoma, a cancer of the bone, and found that 
its overexpression affected the intracellular expression of β-catenin, thus affecting the invasion 
and proliferation of osteosarcoma cells. A western blot showed that BAMBI expression was 4-
fold higher in osteosarcoma tissues as compared to normal tissues. Cellular proliferation in a 
human osteosarcoma cell line was evaluated, revealing that BAMBI promoted the transition 
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from G0/G1 to G2/M in the cells. Collectively, this study showed that BAMBI modulated the 
Wnt/β-catenin pathway, suggesting that it can upregulate the invasion and migration of 
osteosarcoma cells. Additionally, BAMBI enhances cell viability by regulating the cell cycle in 
the presence of cyclin D1.  
 
 
 
 
Figure 12. TGF- R1 and R2 signaling. BAMBI exhibits similarity to TGF- R1 signaling, but 
lacks the intracellular kinase domain. 
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Five Week Staining Results 
 It appears in the 5-week time point that there is more cartilage development in the 
ITGAV Guide 3 knockdown fish, whereas the SLC30A9 fish appears similar to the control. 
Without the genotyping of these fish, we are unable to draw a definitive conclusion about 
whether the increased cartilage in the ITGAV knockdown is caused by a mutation. Likewise, we 
are unable to conclude whether the SLC30A9 similarity in the control is caused by a mutation or 
lack of one. Thus, the 8-week staining and genotyping will provide further insight into whether 
the preliminary results with the 5-week staining is confirmed in further development.  
 The multiple deaths seen within both the SLC30A9 and the ITGAV knockdowns can be 
caused by several different factors. The injection process is often harsh on embryos and can 
cause skeletal abnormalities or even death. This is evidenced by the fact that many of the control 
embryos died, as well. Also, there is a possibility that the fish that died were positive for the 
knockout and it ended up killing them before analysis could be performed. Thus, it is necessary 
to perform further studies with these genes and inject another round of embryos for analysis and 
germline transmission.  
BAMBI Overexpression 
 After functional analysis of the three candidate mutations within the CS-64 family, it is 
predicted that the disease causing mutation is found within the BAMBI gene. This hypothesis is 
primarily based upon the analysis of previous studies of BAMBI functions. It is predicted that 
the craniosynostosis phenotype is caused by an overexpression due to the lack of a phenotype 
shown in mouse knockout studies. Further investigation of the BAMBI gene requires 
generational analysis in zebrafish using the overexpression vector created within this study.  
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Future Studies 
 Future studies determining causes of nonsyndromic craniosynostosis will continue with 
the 100 samples that have been collected through the VCU Center for Craniofacial Care. We 
speculate that nonsyndromic craniosynostosis is a polygenic disorder, a disorder that can be 
caused by mutations in different genes. This prediction is supported by the identification of the 
candidate mutations within the CS-64 family compared with the lack of mutations found within 
the CS-14 family, where the affected individuals in both families presented with sagittal 
synostosis. Further sequencing and identification of candidate mutations with the individuals that 
we have collected DNA from will allow a better look into nonsyndromic craniosynostosis of all 
types.  
 For the BAMBI gene, we predict that overexpression studies in zebrafish will have an 
effect on skull suture formation. Generational studies will be performed in order to obtain 
homozygous mutants for the Bambia gene and evaluated the effect of the overexpression. As 
previously stated, zebrafish have two homologs of the BAMBI gene. Further analysis of the 
BAMBI would require testing with the Bambib gene in zebrafish. Analysis of the Bambi 
homologs has not yet been performed in order to determine whether both perform the same 
function or have slightly differing functions, thus indicating the need for this analysis. Further 
studies are needed for the ITGAV and SLC30A9 knockdown lines as well, in order to perform 
germline transmission analysis. 
 If overexpression analysis of BAMBI returns no significant findings, there is the 
possibility of a multigenic component to the individuals within the CS-64 family. In order to 
investigate this possibility, future studies can involve differing combination of ITGAV, 
SLC30A9, or BAMBI. Due to the prediction that SLC30A9 and ITGAV mutations decrease the 
stability of the protein, an overexpression of BAMBI with a knockdown of SLC30A9 or ITGAV 
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should be explored. In the event that no phenotype is found involving any combination of these 
three genes, WGS should be studied to determine whether there is a mutation within an intron or 
modifier gene causing the phenotype. As stated with the CS-14 family, WGS will allow a look at 
the 15% of mutations that can be missed in WES.  
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Appendix 
 
java -Xms256m -Xmx1300m  
-jar ./kggseq/kggseq.jar  
--buildver hg19  
--resource ./resource  
--no-resource-check  
--no-lib-check  
--out ./Trio1Rec 
--excel  
--vcf-file craSyn-Trio1.recode.vcf  
--ped-file craSyn.ped  
--genotype-filter 1,2,6  
--seq-qual 30  
--seq-mg 20  
--seq-sb -10  
--gty-qual 20  
--gty-qual 8  
--db-gene refgene  
--gene-feature-in 0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15 
--db-filter hg19_1kg201204,hg19_dbsnp138,hg19_ESP6500AA,hg19_ESP6500EA  
--rare-allele-freq 0.01 
--db-score dbnsfp  
--mendel-causing-predict all  
--genome-annot  
--omim-annot  
--candi-list 
ALX4,BBS9,BMP2,BMP3,BMP4,BMP7,C1QTNF3,CYP26B1,EFNA4,ENFB1,MAPK1,ERK2,
ERK1,ERF,FAM20C,FBN1,FGF2,FGF7,FGF8,FGF9,FGFR1,FGFR2,FGFR3,FREM1,GLI3,GP
C3,IGF1R,IGF2R,IGFB3,IGFBP1,IGFBP5,IL11RA,KRAS,LMX1B,LRIT3,MCPH1,MSX2,NE
LL1,ORC1,POR,RAB23,RBP4,RECQL4,RUNX2,SFRP4,SKI,SNAI1,SOX6,TCF3,TCF12,TCO
F1,TGFB3,TGFBR1,TGFBR2,TWIST1,TWISTNB,WDR35,VCAM1,ZIC3  
--ppi-annot-string  
--ppi-depth 1 
 
 
Appendix Ia. KGGseq script for CS-39 trio family. Recessive Filtering 
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java -Xms256m -Xmx1300m  
-jar ./kggseq/kggseq.jar  
--buildver hg19  
--resource ./resource  
--no-resource-check  
--no-lib-check  
--out ./Trio1Denovo 
--excel  
--vcf-file craSyn-Trio1.recode.vcf  
--ped-file craSyn.ped  
--genotype-filter 7 
--seq-qual 30  
--seq-mg 20  
--seq-sb -10  
--gty-qual 20  
--gty-qual 8  
--db-gene refgene  
--gene-feature-in 0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15 
--db-filter hg19_1kg201204,hg19_dbsnp138,hg19_ESP6500AA,hg19_ESP6500EA  
--rare-allele-freq 0.01 
--db-score dbnsfp  
--mendel-causing-predict all  
--genome-annot  
--omim-annot  
--candi-list 
ALX4,BBS9,BMP2,BMP3,BMP4,BMP7,C1QTNF3,CYP26B1,EFNA4,ENFB1,MAPK1,ERK2,
ERK1,ERF,FAM20C,FBN1,FGF2,FGF7,FGF8,FGF9,FGFR1,FGFR2,FGFR3,FREM1,GLI3,GP
C3,IGF1R,IGF2R,IGFB3,IGFBP1,IGFBP5,IL11RA,KRAS,LMX1B,LRIT3,MCPH1,MSX2,NE
LL1,ORC1,POR,RAB23,RBP4,RECQL4,RUNX2,SFRP4,SKI,SNAI1,SOX6,TCF3,TCF12,TCO
F1,TGFB3,TGFBR1,TGFBR2,TWIST1,TWISTNB,WDR35,VCAM1,ZIC3  
--ppi-annot-string  
--ppi-depth 1 
 
 
Appendix Ib. KGGseq script for CS-39 trio family. De novo filtering.  
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java -Xms256m -Xmx1300m  
-jar ./kggseq/kggseq.jar  
--buildver hg19  
--resource ./resource  
--no-resource-check  
--no-lib-check  
--out ./3Gen 
--excel  
--vcf-file craSyn-3Gen.recode.vcf  
--ped-file craSyn.ped  
--genotype-filter 3,4,5 
--seq-qual 30  
--seq-mg 20  
--seq-sb -10  
--gty-qual 20  
--gty-qual 8  
--db-gene refgene  
--gene-feature-in 0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15 
--db-filter hg19_1kg201204,hg19_dbsnp138,hg19_ESP6500AA,hg19_ESP6500EA  
--rare-allele-freq 0.01 
--db-score dbnsfp  
--mendel-causing-predict all  
--genome-annot  
--omim-annot  
--candi-list 
ALX4,BBS9,BMP2,BMP3,BMP4,BMP7,C1QTNF3,CYP26B1,EFNA4,ENFB1,MAPK1,ERK2,
ERK1,ERF,FAM20C,FBN1,FGF2,FGF7,FGF8,FGF9,FGFR1,FGFR2,FGFR3,FREM1,GLI3,GP
C3,IGF1R,IGF2R,IGFB3,IGFBP1,IGFBP5,IL11RA,KRAS,LMX1B,LRIT3,MCPH1,MSX2,NE
LL1,ORC1,POR,RAB23,RBP4,RECQL4,RUNX2,SFRP4,SKI,SNAI1,SOX6,TCF3,TCF12,TCO
F1,TGFB3,TGFBR1,TGFBR2,TWIST1,TWISTNB,WDR35,VCAM1,ZIC3  
--ppi-annot-string  
--ppi-depth 1 
 
 
Appendix Ic. KGGseq script for CS-58 three generation family. Dominant filtering.  
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java -Xms256m -Xmx1300m  
-jar ./kggseq/kggseq.jar  
--buildver hg19  
--resource ./resource  
--no-resource-check  
--no-lib-check  
--out ./Trio2 
--excel  
--vcf-file craSyn-Trio2.recode.vcf  
--ped-file craSyn.ped  
--genotype-filter 3,4,5 
--seq-qual 30  
--seq-mg 20  
--seq-sb -10  
--gty-qual 20  
--gty-qual 8  
--db-gene refgene  
--gene-feature-in 0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15 
--db-filter hg19_1kg201204,hg19_dbsnp138,hg19_ESP6500AA,hg19_ESP6500EA  
--rare-allele-freq 0.005 
--db-score dbnsfp  
--mendel-causing-predict all  
--genome-annot  
--omim-annot  
--candi-list 
ALX4,BBS9,BMP2,BMP3,BMP4,BMP7,C1QTNF3,CYP26B1,EFNA4,ENFB1,MAPK1,ERK2,
ERK1,ERF,FAM20C,FBN1,FGF2,FGF7,FGF8,FGF9,FGFR1,FGFR2,FGFR3,FREM1,GLI3,GP
C3,IGF1R,IGF2R,IGFB3,IGFBP1,IGFBP5,IL11RA,KRAS,LMX1B,LRIT3,MCPH1,MSX2,NE
LL1,ORC1,POR,RAB23,RBP4,RECQL4,RUNX2,SFRP4,SKI,SNAI1,SOX6,TCF3,TCF12,TCO
F1,TGFB3,TGFBR1,TGFBR2,TWIST1,TWISTNB,WDR35,VCAM1,ZIC3  
--ppi-annot-string  
--ppi-depth 1 
--pubmed-mining bone,skull,craniosynostosis,suture 
 
 
Appendix Id. KGGseq script for CS-64 trio family. Dominant Filtering 
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java -Xms256m -Xmx1300m  
-jar ./kggseq/kggseq.jar  
--buildver hg19  
--resource ./resource  
--no-resource-check  
--no-lib-check  
--out ./MZ 
--excel  
--vcf-file craSyn-MZ.recode.vcf  
--ped-file craSyn.ped  
--genotype-filter 2,4 
--seq-qual 30  
--seq-mg 20  
--seq-sb -10  
--gty-qual 20  
--gty-qual 8  
--db-gene refgene  
--gene-feature-in 0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15 
--db-filter hg19_1kg201204,hg19_dbsnp138,hg19_ESP6500AA,hg19_ESP6500EA  
--rare-allele-freq 0.01 
--db-score dbnsfp  
--mendel-causing-predict all  
--genome-annot  
--omim-annot  
--candi-list 
ALX4,BBS9,BMP2,BMP3,BMP4,BMP7,C1QTNF3,CYP26B1,EFNA4,ENFB1,MAPK1,ERK2,
ERK1,ERF,FAM20C,FBN1,FGF2,FGF7,FGF8,FGF9,FGFR1,FGFR2,FGFR3,FREM1,GLI3,GP
C3,IGF1R,IGF2R,IGFB3,IGFBP1,IGFBP5,IL11RA,KRAS,LMX1B,LRIT3,MCPH1,MSX2,NE
LL1,ORC1,POR,RAB23,RBP4,RECQL4,RUNX2,SFRP4,SKI,SNAI1,SOX6,TCF3,TCF12,TCO
F1,TGFB3,TGFBR1,TGFBR2,TWIST1,TWISTNB,WDR35,VCAM1,ZIC3  
--ppi-annot-string  
--ppi-depth 1 
 
 
Appendix Ie. KGGseq script for CS-14 twin family.  
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Appendix II. (A) A restriction site map of pBluescript SK- vector with green showing the 
location of the Bambia insert and the blue showing BamH1 cut sites (B) Bambia gene showing 
BamH1 cut sites in blue and coding DNA sequence in red. (C) pCSHSP heat shock promoter 
vector with blue showing BamH1 cut sites.  
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Appendix III
 
 
 
 
 
 
            
Chr Position Ref/Alt rsID Gene Gene Feature SIFT Polyphen_HDIV AffRef AffHet AffAlt UnRef UnHet UnAlt 
CS-39 Family: Affected Daughter CS-39     Unaffected Mother CS-54     Unaffected Father CS-55 
       
4 1806153 C/A rs28931615 FGFR3 missense 0.059999999 0.921000004 0 1 0 2 0 0 
CS-64 Family: Affected Daughter CS-64     Unaffected Mother CS-66     Affected Father CS-65 
       
2 187466761 C/T . ITGAV missense 0 1 0 2 0 1 0 0 
4 42068573 T/C . SLC30A9 missense 0.02 0.99599999 0 2 0 1 0 0 
10 28971115 A/G . BAMBI missense 0.300000012 0.96899998 0 2 0 1 0 0 
CS-58 Family: Affected Son CS-58       Affected Mother CA-59      Unaffected Father CS-60      Affected Maternal Grandmother CS-61 
1 11107097 G/A . MASP2 missense 0.01 1 0 3 0 1 0 0 
1 202129691 C/T . PTPN7 stopgain 0.49000001 . 0 3 0 1 0 0 
2 62106135 T/C . CCT4 missense 0.029999999 0.964999974 0 3 0 1 0 0 
2 241447012 C/T . ANKMY1 missense 0.02 0.998000026 0 3 0 1 0 0 
5 78422030 G/A . BHMT missense 0.07 1 0 3 0 1 0 0 
6 123824803 A/G . TRDN missense . . 0 3 0 1 0 0 
9 130954172 C/T . CIZ1 missense . . 0 3 0 1 0 0 
10 123325014 T/C . FGFR2 missense 0 1 0 3 0 1 0 0 
11 123813831 A/T . OR6T1 missense 0 1 0 3 0 1 0 0 
16 1272209 C/G . TPSG1 missense 0.159999996 0.961000025 0 3 0 1 0 0 
17 74155468 G/A . RNF157 missense 0 0.999000013 0 3 0 1 0 0 
18 74074460 C/G . ZNF516 missense 0 0.998000026 0 3 0 1 0 0 
CS-14 Family: Proband CS-14  Unaffected twin: CS-15 
      
1 152195729 T/A . HRNR missense 0 0.51800001 0 1 0 1 0 0 
X 66765161 A/T . AR missense 0.029999999 0.44800001 0 1 0 1 0 0 
CS-2 Family: Unaffected Mother CS-2      Affected Daughter CS-3      Affected Son CS-4      Unaffected Son CS-5      Unaffected Daughter CS-6      Unaffected Father CS-7 
9 14776140 C/T . FREM1 missense 0.050000001 0.06 0 2 0 1 0 0 
9 14819370 G/T . FREM1 missense 0 0.995 0 1 1 0 1 0 
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 Gene Det 
 CS-39 Family: Affected Daughter CS-39     Unaffected Mother CS-54     Unaffected Father CS-55 
 
FGFR3 
FGFR3:NM_022965(16Exons):intronic7;FGFR3:NM_000142(18Exons):exon9:c.C1172A:p.A391E&missense;FGFR3:NM_001163213(18Exons):exon9:c.C1178A:p.A393E&
missense 
 CS-64 Family: Affected Daughter CS-64     Unaffected Mother CS-66     Affected Father CS-65 
 
ITGAV 
ITGAV:NM_001144999(30Exons):exon2:c.C61T:p.L21F&missense;ITGAV:NM_001145000(28Exons):exon2:c.C199T:p.L67F&missense;ITGAV:NM_002210(30Exons):ex
on2:c.C199T:p.L67F&missense 
 SLC30A9 SLC30A9:NM_006345(18Exons):exon13:c.T1079C:p.L360P&missense 
 BAMBI BAMBI:NM_012342(3Exons):exon3:c.A568G:p.M190V&missense 
 CS-58 Family: Affected Son CS-58       Affected Mother CA-59      Unaffected Father CS-60      Affected Maternal Grandmother CS-61 
 MASP2 MASP2:NM_139208(5Exons):exon2:c.C85T:p.R29C&missense;MASP2:NM_006610(11Exons):exon2:c.C85T:p.R29C&missense 
 
PTPN7 
PTPN7:NR_037663(10Exons):ncRNA;PTPN7:NR_037664(9Exons):ncRNA;PTPN7:NM_080588(9Exons):upstream-
572;PTPN7:NM_001199797(10Exons):intronic1;PTPN7:NM_002832(10Exons):exon1:c.G245A:p.W82*&stopgain 
 CCT4 CCT4:NM_006430(14Exons):exon5:c.A391G:p.T131A&missense;CCT4:NM_001256721(13Exons):exon4:c.A301G:p.T101A&missense 
 
ANKMY1 
ANKMY1:NM_001282780(14Exons):intronic9;ANKMY1:NM_001282771(18Exons):exon13:c.G2491A:p.E831K&missense;ANKMY1:NM_001282781(17Exons):exon12:c.
G1507A:p.E503K&missense;ANKMY1:NM_016552(17Exons):exon12:c.G2224A:p.E742K&missense;ANKMY1:NM_017844(14Exons):exon9:c.G1552A:p.E518K&missens
e 
 BHMT BHMT:NM_001713(8Exons):exon6:c.G787A:p.D263N&missense 
 
TRDN 
TRDN:NM_001256020(9Exons):intronic8;TRDN:NM_001251987(21Exons):intronic8;TRDN:NM_006073(41Exons):intronic8;TRDN:NM_001256021(8Exons):exon8:c.T85
4C:p.M285T&missense 
 
CIZ1 
CIZ1:NM_001131016(17Exons):upstream-304;CIZ1:NM_001131018(17Exons):upstream-304;CIZ1:NM_001131017(18Exons):upstream-
304;CIZ1:NM_001257976(16Exons):upstream-
304;CIZ1:NM_012127(17Exons):intronic1;CIZ1:NM_001131015(18Exons):intronic1;CIZ1:NM_001257975(18Exons):exon1:c.G47A:p.R16Q&missense 
 
FGFR2 
FGFR2:NR_073009(17Exons):ncRNA;FGFR2:NM_001144919(17Exons):intronic2;FGFR2:NM_001144918(16Exons):intronic2;FGFR2:NM_001144915(17Exons):intronic2;
FGFR2:NM_001144916(15Exons):intronic1;FGFR2:NM_023029(16Exons):intronic1;FGFR2:NM_001144913(17Exons):exon2:c.A314G:p.Y105C&missense;FGFR2:NM_00
0141(18Exons):exon3:c.A314G:p.Y105C&missense;FGFR2:NM_022970(18Exons):exon3:c.A314G:p.Y105C&missense;FGFR2:NM_001144917(16Exons):exon3:c.A314G:p
.Y105C&missense;FGFR2:NM_001144914(15Exons):exon2:c.A314G:p.Y105C&missense 
 
OR6T1 
FGFR3:NM_022965(16Exons):intronic7;FGFR3:NM_000142(18Exons):exon9:c.C1172A:p.A391E&missense;FGFR3:NM_001163213(18Exons):exon9:c.C1178A:p.A393E&
missense 
 
TPSG1 
CACNA1H:NM_001005407(34Exons):downstream+437;CACNA1H:NM_021098(35Exons):downstream+437;TPSG1:NM_012467(6Exons):exon5:c.G644C:p.G215A&misse
nse 
 RNF157 RNF157:NM_052916(19Exons):exon12:c.C1252T:p.R418C&missense 
 ZNF516 ZNF516:NM_014643(8Exons):exon8:c.G3485C:p.G1162A&missense 
 CS-14 Family: Proband CS-14  Unaffected twin: CS-15 
 HRNR HRNR:NM_001009931(3Exons):exon2:c.A1T:p.M1L&missense 
 AR AR:NM_000044(8Exons):exon1:c.A173T:p.Q58L&missense 
 CS-2 Family: Unaffected Mother CS-2      Affected Daughter CS-3      Affected Son CS-4      Unaffected Son CS-5      Unaffected Daughter CS-6      Unaffected Father CS-7 
 FREM1 .:FREM1:NM_144966(38Exons):exon26:c.G4504A:p.V1502M&missense;FREM1:NM_001177704(14Exons):exon2:c.G112A:p.V38M&missense 
 FREM1 .:FREM1:NM_144966(38Exons):exon15:c.C2408A:p.S803Y&missense 
Appendix IV 
